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ASSESSING BLOOD BRAIN BARRIER 
DYNAMICS OR IDENTIFYING OR 
MEASURING SELECTED SUBSTANCES OR 
TOXINS IN A SUBJECT BY ANALYZING 
RAMAN SPECTRUM SIGNALS OF 
SELECTED REGIONS IN THE EYE 
RELATED APPLICATIONS 
This application is a continuation-in-part of U.S. appli- 
cation Ser. No. 091690,113, filed Oct. 16, 2000, which is a 
continuation of U.S. application Ser. No. 091351,788, filed 
Jul. 12,1999, now U.S. Pat. No. 6,181,957 which claims the 
benefit of U.S. Provisional Application No. 601092,545, filed 
Jul. 13, 1998, the disclosures of which are hereby incorpo- 
rated by reference as if restated in their entirety herein. 
The invention described herein was made in the perfor- 
mance of work under a NASA contract, and is subject to the 
provisions of Public Law 96-517 (35 USC 9202) in which 
the Contractor has elected to retain title. The United States 
Government has certain rights to this invention. 
FIELD OF THE INVENTION 
The present invention concerns methods and apparatus for 
measuring or identifying the presence of selected substances 
in the body and/or assessing blood brain dynamics of a 
subject via non-invasive spectrographic analysis of certain 
regions of the eye, such as the aqueous humor in the anterior 
chamber of the eye. 
BACKGROUND OF THE INVENTION 
Non-invasive measurement of physiological and foreign 
substances, including blood glucose, by optical spectros- 
copy techniques has remained an elusive target for at least 
two decades. Blood, tissue, and most excreted fluids contain 
numerous substances which confound many spectral signa- 
tures. On the other hand, the aqueous humor (AH), which 
fills the anterior chamber of the eye (between the lens and 
cornea), contains relatively few molecules capable of inter- 
fering with the spectroscopic detection of glucose. These are 
primarily lactate, ascorbate, and urea. This fact, along with 
its optically accessible location behind the cornea, makes the 
AH an attractive choice as a site on which to attempt 
non-invasive analysis of many substances present in a 
biological subject, including glucose. 
Pohjola (Acta Ophthalmologica Suppl. 88, 1-80 (1996)) 
showed that the ratio of aqueous glucose to plasma glucose 
in normal euglycemic individuals is related to age and 
ranges from 0.6 to 0.9. He further showed in seven humans 
with steady-state hyperglycemia that similar ratios applied. 
There is little, if any, data regarding the equilibration time of 
aqueous humor glucose with changes in plasma glucose in 
humans. Some recent research suggests that the glucose 
content of the AH compared with that in the capillary blood 
in man is about 0.75 regardless of the glycemic state of the 
person. See e.g., Schrader et al., The glucose content of the 
aqueous humour compared with capillary blood in man, 
Invest. Ophthalmol. Vis. Sci. (Suppl.) 44:404 (2000). 
Numerous investigators over the years have suggested 
that the ratio of aqueous glucose to plasma glucose in the 
normoglycemic rabbit ranges from 0.42 to 1.01 (S. Pohjola, 
supra; D. Reddy and V. Kinsey, Arch. Ophthalmol. 63, 
715-720 (1960); M. Reim et al., Ophthalmologica 154, 
39-50 (1967); W. March et al., Diabetes Care 5, 259 
(1982)). It is uncertain whether this variability is normal or 
could be attributed to differences in glucose measurement 
2 
techniques, collection techniques, sample storage, and anes- 
thesia. It is believed that the relationship of aqueous glucose 
to rising, or falling, plasma glucose has not been previously 
studied in rabbits. 
Cot6 has reviewed the relative strengths and weaknesses 
of optical glucose sensing techniques (J. Clin. Engineering 
22, 253 (1997)). Raman spectroscopy is potentially attrac- 
tive because it can distinguish glucose in water solutions 
containing various levels of other optically active metabo- 
lites (S. Wang et al.,Applied Optics 32,925 (1993)). Raman 
spectroscopy measures the shift in the wavelength of inci- 
dent light as it is scattered by molecules. Any given mol- 
ecule typically causes a characteristic shift in the spectrum 
of scattered light, which is dependent upon its intermolecu- 
lar and intramolecular bonds. This is in contradistinction to 
fluorescence, which is caused by changes in electron energy 
states, and does not shift relative to the wavelength of 
incident light. 
Wicksted et al, (Appl. Sectroscop. 49,987 (1995)) suggest 
that the Raman signature for glucose can be identified in 
20 aqueous humor samples, and Goetz et al. (ZEEE Tram. 
Biomed. Eng. 42,728 (1995)) have demonstrated that higher 
than physiologic levels of glucose can be measured with 
Raman spectroscopy in water solutions. J. Lambert et al. 
(LEOS Newsletter 12, 19-22 (1998)) suggest that measure- 
2s ment of glucose at physiologic levels is possible in water 
solutions containing other analytes normally found in the 
aqueous humor. In certain situations, when solutions con- 
taining fluorescent substances are studied, however, the 
fluorescence signal may overwhelm the relatively weak 
30 Raman-shifted signal. This is a potential problem if Raman 
spectroscopy is applied to certain regions in the eye, such as 
the conjunctiva or vitreous or aqueous humor (and/or 
depending upon what the Raman signal is attempting to 
identify or measurer), which can contain proteins that fluo- 
U.S. Pat. No. 5,243,983 to Tarr et al. proposes a non- 
invasive blood glucose measurement system using stimu- 
lated Raman spectroscopy. Stimulated Raman spectroscopy 
can require the use of both a pump and a probe laser beam. 
40 In operation, the probe laser beam is used to measure the 
stimulated Raman light at a single wavelength after trans- 
mission across the anterior chamber of the eye.  
Commercially, this may be undesirable, since an optical 
component contacting the eye is used to direct the beam 
45 across the anterior chamber. In addition, use of a single 
wavelength may limit the ability to measure glucose at 
physiologic levels within tissue containing many other 
Raman scattering chemicals. 
Others have also proposed various glucose measurement 
SO devices. For example, U.S. Pat. No. 5,433,197 to Stark 
suggests a non-invasive glucose measurement apparatus that 
employs broadband, infrared light stimulation. In addition, 
U.S. Pat. No. 5,553,617 to Barkenhagen proposes a non- 
invasive method for measuring body chemistry from the eye 
ss of a subject by measuring a spectral response such as a 
Raman scattering response. While the latter reference 
alleges that it may be used for medical applications (such as 
the determination of sugar in diabetics), specific details on 
how this might be accurately carried out are not provided. 
60 Another example is found in U.S. Pat. No. 5,710,30 to 
Essenpreis, which proposes a method for measuring the 
concentration of glucose in a biological sample such as the 
eye (see FIG. 4 therein) with interferometric measurement 
procedures. Still another example is proposed in U.S. Pat. 
65 No. 5,666,956 to Buchert et al., wherein it is proposed that 
an instrument for the non-invasive measurement of a body 
analyte can be based on naturally emitted infrared radiation. 
5 
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In spite of the foregoing efforts, a commercially viable, 
non-invasive monitor which can successfully employ a 
non-invasive optical analysis of certain regions of the eye, 
including the aqueous humor of the eye, has not yet been 
developed. Difficulties in developing such a device include: 
(a) determining reliable correlations of the typical millimo- 
lar quantities of selected substances or chemicals; (b) obtain- 
ing accurate measurements of selected substances; and (c) 
inhibiting damaging effects to the eye which may be caused 
by excessive exposure to light in an instrument hat is used 
Accordingly, there is a continued need for improved 
systems, methods, and devices for the non-invasive in vivo 
analysis of foreign and natural physio~ogic substances in a 
the eye. 
present invention can monitor the presence or concentration 
of the treatment drug itself in the blood aqueous compart- 
ment in the eye. Examples of suitable markers include large 
molecule natural and synthetic substances which do not 
normally Cross the blood brain barrier, including, but not 
limited to, antibiotics such as erythromycin, and conjugated 
substances such as conjugated 
TYPicallY, the treatment drug is configured such that it is 
inhibited from crossing the blood brain barrier. Thus, in 
certain applications, in order to deliver a sufficient quantity 
systemically delivered, can be undesirably toxic to the 
patient away from the targeted treatment region in the brain. 
The present invention can now assess or assure either that 
more efficiently therethrough and/or quantify or assess that 
a sufficient amount of the treatment drug is getting into the 
brain so that the systemic amount can be more closely 
’& present invention provides methods and systems for regulated and reduced. After the desired treatment (or dose) 
monitoring or evaluating the blood aqueous barrier and, 2o is indicated as delivered to the brain, the blood brain barrier 
thus, the blood brain barrier dynamics of the subject. The can be restored such that it is substantially in its pre-altered 
present invention also provides methods which can detect state. The return to the pre-altered state can be confirmed by 
the presence or absence of one or more selected substances 
or analytes of interest in the body by optically analyzing in a reduced concentration in the blood aqueous compart- 
certain regions of the eye, including at least one of the AH, 25 ment in the eye. 
the vitreous humor (“VH’)), and one or more blood vessels By identifying and/or quantifying the amount of the 
in the conjunctiva. In certain embodiments, the analysis can non-specific marker present in the aqueous humor (and, thus 
provide information regarding the presence of and/or quan- in the blood aqueous barrier), an estimate or determination 
tify a detected substance in the cerebral spinal or intracranial of the concentration in the brain can be established. 
fluid of the subject (indirectly, through a correlation with the 30 Typically, the concentration in the blood aqueous humor can 
presence or quantification of the substance in the blood be presumed to be similar to that in the blood brain com- 
vessel in the conjunctiva, or the AH or the vitreous humor). partment. Further, the two concentrations can be correlated 
Embodiments of the invention can employ Raman spec- so that a quantitative value of the amount in the cerebral 
troscopy to non-invasively obtain, in vivo, at least one spinal or intracranial fluid can be determined based on that 
signature spectroscopic signal to identify and/or measure the 35 found in the blood aqueous compartment SO that a titrated 
level or concentration of a substance or substances of dose of the treatment drug in the brain may be able to be 
interest in the subject (either in the blood and/or brain) based determined. The correlation relationship or ratio may vary 
on the signal. within certain population segments. In certain embodiments, 
certain embodiments, the present invention can be used the correlation relationship can be determined based on data 
to monitor or evaluate the blood brain barrier dynamics, 40 collected across a representative Population (by age, size, 
which may be intentionally altered (such as through the weight, gender, race, disease or physiological impairment or 
administration of chemicals or exposure to certain environ- abnormality, Or national origin). Thus, the amount of the 
mental conditions such as increased pressure) during such selected treatment drug actually getting into the brain can be 
evaluation, B~ intentionally breaking down the blood brain correlated to the systemic dose delivered to the patient so 
barrier, medicines which are normally inhibited from cross- 45 that the dose or level in the spinal fluid is sufficiently high 
ing the barrier may be allowed to readily cross and for treatment of the tumor or other condition but the sys- 
enter into the brain, T~ monitor such a change in the temic dose is sized to provide reduced toxicity to the subject 
operation or dynamics of the blood brain barrier, non- (by avoiding administering unnecessary quantities to the 
specific markers can be introduced or injected into the Subject). 
subject. The non-specific marker is selected based on its 50 In certain embodiments, the present invention can provide 
molecular size and/or its normal reluctance to cross the methods, similar to that discussed for intentionally altering 
blood brain barrier. The blood brain barrier can then be the dynamics of the blood brain barrier, which use a non- 
s 
to generate the analysis signal spectrum in the AH. Of the drug to the brain, the amount Of drug, which is 
biological subject via optical analysis of certain regions of 15 the barrier is to the drug to pass 
SUMMARY OF THE INVENTION 
taking another optical reading to confirm that the marker is 
intentionally altered (broken down or opened) so that the 
non-specific marker is able to cross therethrough. An optical 
specific marker with a new drug to evaluate the impact that 
a new drug or therapy regimen has on the blood brain barrier 
reading of a selected region of the eye can be taken, and the 5s for safety or other considerations. In other embodiments, the 
present invention can assess whether the marker is present optical detection of the drug itself in certain regions of the 
(either at all or in an increased amount over a pre-alteration eye, without the use of a marker, may be sufficient to 
state) in the blood aqueous barrier. Further, in Some indicate the drug’s impact on the blood brain barrier. 
embodiments, the concentration of the marker in the eye can In other embodiments, the environmental conditions sur- 
be determined (such as in the AH or vitreous humor) in the 60 rounding the patient or subject, can be altered and the 
blood aqueous compartment. If the marker is identified as dynamics of the blood brain barrier monitored. For example, 
being present, this indicates that the blood brain barrier has subjects which are exposed to different elevations, gravity 
been altered. Once the blood brain barrier is altered, a conditions, or to increased intracranial pressure, may exhibit 
desired treatment regimen can be administered to the subject different or altered blood brain barrier characteristics, either 
(such as drug used for chemotherapy) to treat tumors or 65 transiently, or more chronically, than persons not so 
other conditions in the eyes or brain. In some embodiments, exposed. These subjects may include astronauts, pilots, 
as an alternative to the use of non-specific markers, the divers, trauma victims, and the like. Evaluating the blood 
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brain barrier dynamics can identify whether larger mol- ciated with bacterial infections such as spinal meningitis, or 
ecules or pathogens are able to cross the blood brain barrier, to identify whether proteins or antibodies are present in 
which may, under normal circumstances, be inhibited or elevated levels to identify a systemic response or a localized 
the present invention can be used to assess which constitu- 5 response, in the subject, 
ents in the blood cross into the intracranial fluid via the In certain embodiments, the systems and methods of the blood brain barrier. present invention may be able to detect or identify toxins 
patient can undergo a treatment regimen to deliberately or poisoning bacteria such as E coli, salmonella (either in vivo intentionally alter the blood brain barrier dynamics so that 
10 or in vitro). Further, in some embodiments, the methods and an identified treatment agent(s) is allowed to cross the systems of the present invent may be used to identify the barrier. For example, an osmotic agent such as a drug (for presence of mad cow disease by analyzing certain regions of example, MANATOL) can be delivered to a subject being the eye (either in vitro or in vivo) such as by obtaining a treated for cancer to force the blood brain barrier to open Raman spectrum of a desired region of the eye analyzing the (preferably for a limited-time treatment window) to success- 
15 spectrum to detect the presence of small peptides or other fully allow a selected chemotherapeutic agent (such as a markers associated with the disease. Other diseases may be cytotoxic agent) to be able to more readily cross the blood able to be identified in vivo by the presence of a systemic brain barrier into the brain. Non-invasive monitoring of the reaction (such as an increased constituent level of a natural tumor dose according to the present invention, can allow physiologic substance) in the subject. It is anticipated that monitoring of the barrier dynamics and may, in some 
20 such a method may be potentially used to assess whether the embodiments, be able to assess when an adequate, but not subject has contracted Lyme disease associated with deer excessive, tumor dose is delivered to the brain. The blood tick bites or Rocky Mountain spotted fever. brain barrier can be reestablished after the appropriate tumor 
dosing is delivered, This monitoring of the blood brain In some embodiments, the invention can identify the 
barrier dynamics during a treatment regimen may now presence of one or a plurality of household or environmental 
inhibit or reduce systemic damage in the subject associated 25 poisons in the subject in a relatively fast “triage” assessment 
with the cytotoxic treatment. to allow clinicians to determine the appropriate treatment in 
prevented from entering the brain. In certain embodiments, infection or disease in the eye or an immune system 
AS generally described above, in One a released or emitted from foods contaminated with food 
In other embodiments, the present invention provides a manner. This can be particularly important for 
where the substance ingested may be systems and for detecting the presence of a prede- pediatric 
termined substance or identifying the presence of an 3o difficult to ascertain for young children, and a relatively 
substance in the body of a subject, The substances quick identification of a particular toxin or toxins ingested 
which can be measured or identified are and can may allow more reliable or faster treatment decisions to be 
be (a) natural physiologic analytes or chemicals, such as 
glucose, amino acids, peptides, antibodies, blood (typically One embodiment of the invention is directed to an in vivo 
using light outside the red spectrum), and/or (b) foreign 35 method for monitoring the blood brain barrier dynamics of 
substances such as medicaments, drugs, or poisons (whether a subject, comprising the step of monitoring the dynamics of 
legal or illegal, and whether prescription or Over the the blood brain barrier by non-invasively obtaining the 
counter). For example, the present invention can be used to lbman spectrum of a selected region in the eye of the 
assess the presence of targeted illegal substances, such as subject. The method may also include the step administering 
alcohol or illegal narcotics such as cocaine, pcp, marijuana, 40 a non-specific marker to the subject selected for its normal 
or to identify what toxin or poison a subject has injested out reluctance to cross the blood brain barrier under the normal 
of a number of household or environmental toxins and/or condition. The monitoring step can comprise detecting the 
poisons such as herbicides, pesticides, household cleaning presence of the non-specific marker in the selected region of 
products, petroleum products or other common house hold the eye of the subject. 
chemicals including benzene, ethylene glycol. The methods 45 In certain embodiments, the method can include the steps 
and systems of the instant invention may even be used to of  altering the dynamics of the blood brain barrier of the 
identify the presence of poisonous plants, insect toxins, and subject from a normal condition; and administering a quan- 
reptile or snake venom. The present invention may be tity of a selected therapeutic agent to a subject for treatment 
configured to identify whether an unknown substance in a of condition in the brain or neurological system after the 
subject is one or more of toxins/agents associated with the so altering step. It can also include the step of substantially 
most prevalent poison-related emergency room visits. For returning the blood brain barrier to its normal state after a 
example, ethylene glycol, methanol, and acetaminophen. sufficient quantity of the therapeutic agent has been deliv- 
In certain embodiments, the present invention can be used ered to the brain. Similarly, the monitoring step can be 
to quantify the amount of the substance in the subject, performed before the therapeutic drug is administered to the 
typically this embodiment may be particularly suitable for 5s subject and subsequently to confirm that the blood brain 
those substances ingested in relatively large quantities or barrier is substantially returned to its normal condition. The 
those present in sufficient quantity in the selected region of method may also include the step of assessing the dose 
the eye so as to be detectable in vivo, or so that the substance amount of the therapeutic agent delivered to the brain. 
or analyte is present in physiological levels (in the blood or Certain embodiments of the present invention are directed 
blood aqueous compartment) of above about 0.001% or 60 to an in vivo a non-invasive method for determining the 
above about 1-10 pmolars, depending on the Raman active level of an analyte of interest in a biological subject. Raman 
characteristics of the analyte of interest. spectroscopy can be used to obtain the signature of the 
In addition, in certain embodiments, the devices and substance in the eye (such as in the AH, VH, or blood vessel 
methods of the present invention may be used to detect in the conjunctiva) and, in some embodiments, to measure 
increased or decreased levels of physiologic analytes such as 65 the concentration of a natural physiologic or foreign 
caused by system impairments or reactions associated with substance, such as glucose and/or proteins, or drugs, alcohol, 
dehydration, allergic reactions, or physiologic analytes asso- environmental or household toxins, in the subject. The 
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method can include the steps of  (a) generating an excitation 
laser beam (e.g., at a wavelength of from about 600 to 900 
nanometers); (b) focusing the excitation laser beam into the 
eye of the subject so that a selected region of the eye is 
illuminated; (c) detecting (preferably confocally detecting) a 
Raman spectrum from the illuminated region of the eye; (d) 
comparing the Raman spectrum from the detecting step to 
predetermined spectrums corresponding to different analytes 
of different concentrations; and (e) identifying the presence 
of an analyte of interest based on the detecting and com- 
paring steps. 
In some embodiments, an additional step ( f )  can be 
performed to determine the blood or brain level of an analyte 
of interest for the subject from the Raman spectrum. The 
blood or brain level may be indirectly computated based on 
the concentration or amount of the analyte in the blood 
aqueous compartment (or can be directly measured in the 
blood itself for the conjunctiva vessel measurement). For the 
indirect measurement, that value can be correlated (or 
adjustedicorrected) to provide an assessment of the amount 
of the substance in the cerebral spinal fluid or blood. The 
correlation may be such that the amount of the substance 
directly measured in the AH is substantially similar to that 
in the cerebral spinal fluid. Alternatively, data correlating the 
relationship can be established and an empirical or statistical 
model established. 
Although not required, in some embodiments, the detect- 
ing step can be followed by the step of subtracting a 
confounding fluorescence spectrum from the Raman spec- 
trum to produce a difference spectrum; and determining the 
blood level of the analyte of interest for the subject from that 
difference spectrum, preferably using linear or nonlinear 
multivariate analysis such as partial least squares or artificial 
neural network algorithms. This technique may be particu- 
larly suitable where fluorescence is problematic for optical 
measurements taken directly of the blood level (i.e., by 
focusing at the blood vessels in the conjunctiva or at the 
vitreous humor). 
In certain embodiments, a low energy excitation wave can 
be used to generate the Raman signal spectrum. “Low 
energy”, as used herein, means power which is on the order 
of about 1 0 4 0 0  mJ or less, and typically between about 
70-330 mJ. The energy exposure will depend on the power 
and pulse length of the excitation pulse. Longer wavelength 
pulses (i.e., above 700) may be used, typically with energy 
levels closer to the higher end of the scale, while lower 
wavelengths (600-700) may be used with lower energy 
exposure levels. In one embodiment, a wavelength of about 
633 nm can be used for a pulse of about 5-10 seconds 
corresponding to about a 2-5 mW power exposure level (and 
between a 10-20 or 25-50 mJ energy exposure to the 
patient’s eye (or eyes)) for each measurement or monitoring 
signal obtained. In other embodiments, an optical excitation 
pulse may have a 785 nm wavelength, a pulse length of 
about 20 ms-5 s and a power rating of about 14-16 mW. In 
one embodiment, a 5 sec, 16 mW pulse can be used to obtain 
the in vivo reading of a cancer agent in the selected region 
of the eye (typically the AH). 
In some embodiments, the excitation beam can be trans- 
mitted such that it presents a reduced energyidensity expo- 
sure rating to the tissue of the eye by shaping the beam to 
increase the cone angle or span of the excitation beam as it 
enters the eye to expose more of the area of the retina and 
reduce the energyiarea rating of the excitation pulse to 
provide improved margins of safety (placing the energyiarea 
rating sufficiently below the threshold of damage). In other 
embodiments, the transmission path numerical aperture is 
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substantially matched to the return path numerical aperture 
(of the spectrometer). 
A second aspect of the present invention is an apparatus 
for the non-invasive in vivo determination of the blood level 
of an analyte of interest in a subject. The apparatus includes 
a laser source for generating an excitation laser beam (e.g., 
at a wavelength of from about 600 to 900 nanometers) and 
an optical system (e.g., a confocal optical system) opera- 
tively associated with the laser for focusing the excitation 
laser beam into a selected region of the eye, including one 
or more blood vessels in the conjunctiva of the eye, the 
vitreous humor, or the anterior chamber of an eye (or eyes) 
of the subject so that the aqueous humor in the desired 
region of the eye is sufficiently illuminated. The apparatus 
also includes a detector operatively associated with the 
optical system and configured to detect a Raman spectrum 
from the selected illuminated region of the eye and a 
processor with computer program code for identifying the 
presence of one or more selected substances or analytes of 
interest. The computer code may also include code for 
determining the in vivo level of the analyte of interest in the 
selected region of the eye and to establish an estimate or 
measure of the analyte in the blood or cerebral spinal fluid 
to be established based on a correlation thereto for the 
subject from the Raman spectrum. 
Focusing the optical analysis on the blood vessels in the 
conjunctiva can allow for a direct measurement of the 
substance in the blood, while the measurements taken from 
other portions of the eye can be correlated to provide an 
estimate or quantification of the substance in the blood 
and/or in the cerebral spinal fluid (i.e., indirect 
measurements). The correlation’s can be established based 
on empirical models or actual measurements taken in vitro 
or in vivo on a representative animal or human population as 
is well known to those of skill in the art. 
In certain embodiments, the apparatus can be configured 
as a low energy unit to inhibit the exposure of the tissue 
during the operation of the apparatus. The excitation wave- 
length at the low power may be less than 700 nm, such as 
about 633 nm. 
Numerous additional features may be incorporated into 
the apparatus. The device may include a visual display 
screen for presenting visual indicia to the user, which can be 
individually adjusted and focused to the particular visual 
acuity of the subject (similar to vision screening focusing 
procedures). The apparatus may include a visual display 
screen for visually displaying the results of the test to the 
subject (such as through the same aperture or adjacent active 
matrix screen) as which the test is conducted. It may include 
a visual fixation target or device, also visible through the test 
aperture, which controls movement of the eye and simulta- 
neously insures that focusing of the laser beam is properly 
directed into the anterior chamber of the eye. The processor 
may contain empirical models of actual testing experience to 
either determine the blood level or concentration of the 
analyte of interest or to identify the presence of selected 
substances. The apparatus may employ a laser of fixed 
wavelength, a tunable laser (which can sample a plurality of 
Raman scattered light (at different wavelengths) 
concurrently), a plurality of fixed wavelength lasers, or other 
light source means some of which can include means for 
sliding the Raman spectrum passed a plurality of different 
wavelength detectors to obviate the need for a full grating 
based Raman spectrometer (by taking a plurality of 
samples). The apparatus may include a wireless or remote 
communication line operably associated with the processor 
for transmitting the blood level of the analyte of interest to 
a remote location (such as for emergency home calls to an 
ER room). 
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Another aspect of the present invention is an in vivo 
method for administering drug or chemical therapy to a 
subject (such as for treatment of a cancerous tumor in the 
brain). The method includes the steps of: (a) administering 
a dose of a selected therapeutic agent to a subject; (b) 5 
altering the dynamics of the blood brain barrier from its 
normal state; (c) monitoring the dynamics of the blood brain 
barrier by non-invasively obtaining the Raman spectrum of 
a selected region in the eye (such as the vitreous or aqueous 
paring steps in the selected region of the eye. The method 
may also be able to estimate the dose or affirm the presence 
of the analyte in the subject's cerebral spinal fluid. 
Yet another aspect of the present invention is a method for 
identifying an alteration in the blood brain barrier of a 
biological subject, comprising the steps of: (a) Don- 
invasivelY obtaining a first in Vivo Raman spectrum of the 
aqueous humor of the subject; (b) non-invasively obtaining 
a second in Raman spectrum Of the aqueous humor Of 
humor) and determining the quantity of the agent therein, 10 the subject; and ('1 identifying an 
The method may also include one or more of (d) estimating 
in the 
brain barrier by the first and second Raman 
the dose of the therapeutic agent delivered to the brain spectrums' 
(indirectly, based on the amount detected in the selected An additional aspect of the present invention is a method 
for identifying an alteration in the blood brain barrier of a region of the eye) (e) repeating said monitoring step a biological subject, comprising the steps of: (a) non- 
returning the blood brain barrier to its normal state after a aqueous humor of the subject; (b) obtaining a reference 
sufficient quantity of agent has been delivered to the brain. spectrum of an in vitro sample representing the aqueous 
In one embodiment, the altering step can be carried out by humor and comprising at least one selected analyte; and (c) 
introducing a chemical to the subject to temporarily open the comparing the in vivo Raman spectrum to the reference 
blood brain barrier to allow larger molecules to pass there- 20 spectrum to identify an abnormality in the blood brain 
through. Further, the method can include the step of admin- barrier by detecting the presence of at least one selected 
istering a non-specific marker which is reluctant to or does analyte in the thereby indicating its presence in the 
not normally pass through the blood brain barrier (i.e., is intracranial fluid of the subject. 
typically inhibited from passing therethrough). The optical The at least one selected analyte can be one which 
non-specific marker in the selected region of the eye to presence is indicative of an abnormality or impairment or 
confirm that the blood brain barrier dynamics has been successful intentional alteration of the blood brain barrier 
altered. dynamics. 
Each of the embodiments of the invention may include In another embodiment, the altering step may be carried 
30 computer program products and computational and look-up 
table associated therewith to identify the presence of the out by increasing the intracranial pressure of the subject. 
Another Of the Present invention is a method Of selected substance or substances of interest (and/or calculate 
non-invasively monitoring the blood brain barrier. The the amount or concentration thereof) and to operate or 
method comprises the steps of: (a) generating an excitation control (regulate) the power of the excitation pulse emitted 
beam at a Of from 6oo to 900 nanometers; (b) 35 from the laser, and the illumination and detection of the 
focusing the excitation beam of said generating step into the scattered light, F~~ in certain embodiments, the 
anterior chamber of an eye of the subject SO that aqueous present invention can include a computer program product 
humor in the anterior chamber is illuminated; (c) detecting for determining the identity of an unknown substance in a 
a Raman spectrum corresponding to the illuminated aqueous subject. The product can comprise computer-readable pro- 
humor; and (dl monitoring the m to Predict the behavior Of 40 gram code comprising: (a) computer readable program code 
the blood brain barrier dynamics during exposure to selected for defining at least one signature reference spectrum for at 
conditions based On the detecting (based On the AH least one selected substance of interest; (b) computer read- 
spectrum analysis' indication of the Presence or able program code for analyzing an in vivo obtained Raman 
concentration of selected substances therein). It is antici- spectrum of the aqueous humor of the subject; and 
Pated that the correlation between the b lood-aq~eo~s  and 45 computer readable program code for based evaluating 
blood brain barrier is such that the presence and/or concen- whether the in vivo R~~~~ spectrum correspon~s to at least 
tration in one can be extrapolated to that in the other. one of the at lest one signature reference spectrums by 
Other embodiments focus the excitation beam such that it comparing selected characteristics between the reference 
has an increased or wider cone angle to spread the light spectrum and the in vivo spectrum. 
across more area of the retina. Still other embodiments are various embodiments, the computer readable program 
configured to focus to one Or more blood vessels on the code for defining the different reference spectrums can be for 
conjunctiva or to focus deeper to the vitreous humor. a particular one or a plurality of different selected sub- 
In certain embodiments, the monitoring step can be used stances. Examples of the selected substance(s) include, but 
to assess whether the dynamics thereof alter sufficiently to are not limited to: alcohol, a substance banned for athletes 
allow selected analytes, which would normally be inhibited 5s in competition, a plurality of illegal narcotic substances, and 
from traveling through the blood brain barrier, to pass into a plurality of household products or common poisons for 
the intracranial spinal fluid through the blood brain barrier. humans or animals which are potentially poisonous to a 
In other embodiments, the monitoring step can be carried out subject when ingested. Amaster look-up reference data base 
when a person is under or exposed to extreme conditions providing Raman spectrum data for a large quantity of 
such as when diving, flying, or mountain climbing, or when 60 different poisons or substances can be generated and stored 
suffering from a traumatic head or brain injury, or high at a central database or at local or regional offices, clinics or 
stress, and the like. the like. The computer program can include means for 
The method can also include the steps of comparing the remotely accessing the data such as via the use of an intranet 
Raman spectrum from the detecting step to reference spec- or internet. 
trums corresponding to at least one selected analyte of 65 The present invention will now be described further and 
interest; and identifying the presence of the least one analyte includes other features and analytes that can be included in 
of interest in the subject based on the detecting and com- the methods and apparatus described herein. 
plurality Of times during the administering step; and (f) invasively obtaining a first in vivo Raman spectrum of the 
analysis can monitor any increase (or the presence) of the 25 typically does not cross the blood brain barrier SO that its 
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BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a graph which illustrates the broad spectrum of 
water in the aqueous humor, which, in some situations, can 
obscure the underlying peaks of interest in the Raman 
spectrum. The raw spectrum of rabbit aqueous humor is 
shown taken at 2 slightly different wavelengths (top). The 
difference spectrum (bottom) achieved by subtracting 1 raw 
spectrum from the other reveals a resultant bipolar Raman 
signature. Linear and/or nonlinear multivariate analysis can 
then be applied. 
FIG. 2 is a graph plotting Raman predicted glucose as a 
function of actual glucose concentration. The glucose con- 
centration in aqueous humor from 16 rabbits was estimated 
with Raman spectroscopy and compared to the actual glu- 
cose concentration measured with a commercial glucometer. 
The graph shows the Raman predicted glucose concentration 
after subtracting fluorescence and applying a linear partial 
least square algorithm followed by nonlinear back propaga- 
tion with an artificial neural network. This resulted in a high 
degree of correlation (r2=0.98) of predicted with actual 
glucose concentration. Applying the partial least squares 
algorithm alone resulted in lesser correlation (r2=0.90). 
FIG. 3 is a graph plotting blood glucose as a function of 
time. Blood glucose steadily rises at variable rates in rabbits 
after administration of xylazine anesthesia. One animal 
(rabbit D, filled diamonds) had little change in blood glucose 
for unknown reasons. 
FIG. 4 is a graph plotting aqueous humor glucose as a 
function of blood glucose. Best-fit second-order polynomial 
curves demonstrate the relationship between aqueous humor 
glucose and plasma glucose while plasma glucose is rising 
in 9 animals. Aqueous glucose measurements from the first 
paracentesis of an eye correlate well with simultaneous 
plasma glucose (dark curve). When plasma glucose exceeds 
200 mgidL the relationship is nearly linear (dashed line). 
Aqueous humor glucose exceeds plasma glucose when 
plasma glucose is less than 200 mg/dL. The relationship of 
aqueous humor glucose with plasma glucose is different 
when the aqueous humor sample is obtained as a second 
paracentesis (light curve) suggesting that the initial para- 
centesis disrupts normal glucose homeostasis. 
FIG. 5 schematically illustrates a first embodiment of an 
apparatus of the invention. 
FIG. 6 schematically illustrates a second embodiment of 
an apparatus of the invention. 
FIG. 7a schematically illustrates the method of sliding 
Raman spectra features through a particular detector win- 
dow by changing excitation frequency. 
FIG. 7b schematically illustrates an apparatus of the 
invention that utilizes the method illustrated in FIG. 7a. 
FIG. 8 illustrates a visual fixation display that can be 
utilized in an apparatus of the invention. 
FIG. 9 illustrates a visible readout display that can be 
utilized in an apparatus of the invention. 
FIG. 10a is a schematic illustration of one embodiment of 
a light generation or light pulse system according to the 
present invention. 
FIG. 10b is a schematic illustration of one embodiment of 
a detection system according to the present invention. 
FIG. 1Oc is a schematic of one embodiment of a system 
with a closed loop feedback control system according to the 
present invention. 
FIG. 10d is a schematic of an alternate closed loop 
feedback system according to embodiments of the present 
invention. 
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FIG. 11 is a block diagram of a method for determining 
the presence or the blood level concentration of a selected 
analyte according to certain embodiments of the present 
invention. 
FIG. 12 is a block diagram of a method for identifying the 
presence of at least one selected substance in a selected 
region of the eye of a subject to evaluate the quantity of same 
in the cerebral spinal or intracranial fluid (it being assumed 
that the mechanics of the blood aqueous barrier can be 
10 representative to the blood brain barrier, the same having 
passed through the blood brain barrier) according to certain 
embodiments of the present invention. 
FIG. 13 is a block diagram of a method for monitoring or 
treating a patient by administering a therapeutic agent during 
a chemotherapy session patient according to embodiments 
of the present invention. 
FIG. 14  is a block diagram of a method of monitoring the 
blood brain barrier dynamics of a subject during exposure to 
selected conditions according to embodiments of the present 
invention. 
FIG. 15 is a block diagram of a method for detecting an 
alteration of the function of the blood brain barrier according 
to certain embodiments of the present invention. 
FIG. 16 is a block diagram of a method for identifying an 
abnormality in the blood brain barrier of a subject according 
to embodiments of the present invention. 
FIG. 17 is a flow chart of a method according to one 
embodiment of the present invention. 
FIG. 18 is a schematic illustration of an apparatus con- 
figured to illuminate and obtain the Raman spectrum from 
the vitreous humor of the eye according to embodiments of 
the invention. 
FIG. 19 is a schematic illustration of an apparatus con- 
35 figured to illuminate and obtain the Raman spectrum of one 
or more blood vessels in the conjunctiva of the eye accord- 
ing to embodiments of the invention. 
FIGS. 20A-20C illustrate optical power density calcula- 
4o tions performed using a canonical model of the adult eye of 
a human. FIG. 20A is a model of the human eye. FIG. 20B 
is a schematic of a portion of the eye illustrating the angles 
an equations associated with power density. FIG. 20C is a 
graph of the power for exposed retinal area and the power 
45 density (assuming a 30 mW input) are shown as a function 
of the angle of incidence. 
FIGS. 21A-21C are graphs of the Raman spectrum of 
artificial and actual aqueous humor samples. FIG. 21A 
corresponds to an ensemble spectrum of artificial aqueous 
humor samples in a model (artificial or test) anterior cham- 
ber. FIG. 21B corresponds to an in vitro ensemble spectrum 
of actual aqueous humor in a model anterior chamber. FIG. 
21C corresponds to in vivo ensemble spectrum of aqueous 
humor. 
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55 DETAILED DESCRIPTION OF EMBODIMENTS 
OF THE INVENTION 
The present invention will now be described more fully 
hereinafter with reference to the accompanying figures, in 
60 which embodiments of the invention are shown. This inven- 
tion may, however, be embodied in many different forms and 
should not be construed as limited to the embodiments set 
forth herein. Like numbers refer to like elements throughout. 
In the figures, layers, components, or features may be 
The term “glucose” as used herein preferably refers to 
D-glucose. The term “subject”as used herein refers to both 
65 exaggerated for clarity. 
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human subjects and animal subjects having circulatory sys- 
tems including domestic large and small animals such as 
dogs, cats, rabbits, horses, cows, pigs, and the like. Animal 
subjects may be used in the present invention for veterinary 
purposes. The present invention may be particularly suitable 
for human subjects. The optical analysis may be performed 
on selected regions of the eye, including the blood vessels in 
the conjunctiva (i.e., one or more of the conjunctiva blood 
vessels located on the surface of the eye), the vitreous humor 
(the (“VH’) or the aqueous humor (the “AH”). 
In certain embodiments, the present invention is primarily 
concerned with the determination of (a) the blood levels or 
(b) the brain fluid level, meaning the intracranial or cerebral 
spinal fluid levels, of selected substances or analytes of 
interest such as may be predicted by the presence and/or 
concentration of the substance or analyte in the selected 
region of the eye of a subject (typically, the AH or the 
conjuctiva vessel(s)). 
In certain embodiments, the present invention recognizes 
that the mechanics of the blood aqueous barrier and the 
blood brain barrier are substantially the same such that, if the 
substance of analyte passes through the blood aqueous 
barrier, it can be presumed to also pass through the blood 
brain barrier. The correlation of the amount that passes 
through the blood brain barrier may be substantially equiva- 
lent to that detected in the eye or may be at a lesser or greater 
concentration. However, the blood concentration of other 
Raman-active molecules, analytes, or substances which do 
not typically pass through the blood brain barrier may also 
be determined by these techniques. Similarly, the amount or 
presence of the selected substance or molecule, etc., in the 
eye itself can be determined by these techniques (such as to 
treat localized in the eye or non-systemic diseases such as 
cancers of the eye). 
As used herein, the term “analyte” is used interchange- 
ably with “substance” to identify a selected target chemical, 
molecule or molecules, either in its blood-absorbed or 
partially absorbed, uptaken, or constituent form, or in an ex 
vivo formulation, where applicable. As such, the substance 
or analyte can include a chemical compound or composition, 
whether synthetic or natural, as well as a constituent thereof 
or molecule of interest. In some embodiments, the analyte or 
substance can be one that is emitted by the body (sometimes 
in an elevated amount) in response to a disease or physi- 
ologic reaction to a product or toxin and may also be a 
byproduct of the body’s reaction to a substance. As such, as 
noted in the summary of the invention above, the substances 
which can be measured or identified according to the present 
invention are numerous and can include (a) natural physi- 
ologic substances, analytes or chemicals, such as glucose, 
amino acids, peptides, blood, or other components of or in 
blood, or in the eye and/or (b) foreign or synthetic or 
artificial substances such as medicaments, drugs, or poisons 
(whether legal or illegal, and whether prescription or over 
the counter) which may be present in the subject. For 
example, the present invention can be used to identify or 
assess the presence (or absence) of and/or the blood level or 
concentration of lactate, urea, benzene, ascorbate alcohol, 
ethanol, methanol, ethylene glycol, steroids, nicotine, or 
illegal narcotics such as cocaine, other opiate-based drugs, 
or prevalent or pervasive designer drugs, or metabolites, or 
household, organic, or environmental toxins and/or poisons 
such as herbicides, pesticides, household cleaning products, 
petroleum products or other chemicals. 
For quantification purposes, the present invention may be 
particularly suitable for identifying the amount of 
substances, which present in the selected region of the eye 
14 
in sufficient quantities to allow Raman based detection. For 
example, a substance which is present in an amount of at 
least about 1-10, and preferably about 1&100 pmolars in 
the AH may be detectable, particularly if the substance is a 
5 Raman active molecule with enhanced resonance at a par- 
ticular selected excitation light wavelength. In some 
embodiments, the targeted analyte may be present in the 
selected or targeted region of the eye in an amount of at least 
about 1 millimolar or in a physiological concentration level 
of about at least 0.001%. The present invention may also be 
able to identify the presence of, or a physiologic reaction to, 
substances associated with poisonous plants, insect or arach- 
nid poison, and reptile or snake venom, in the subject. 
In addition, in certain embodiments, the devices and 
methods of the present invention may be used (to analyze 
either iii vitro or in vivo) to detect increased or decreased 
levels of physiologic analytes in the blood or to detect 
certain disease processes of known conditions. For example, 
by identifying increased or decreased levels of certain 
substances in the body or the presence in the subject of 
20 certain peptides or toxins associated with a particular 
condition, such as those caused by system impairments or 
reactions associated with dehydration, allergic reactions, 
toxins from bacterial infections such as spinal meningitis, or 
elevated or decreased levels of antibodies to identify an 
25 immune system response, or even hormones evoked in 
response to a pregnancy. 
In certain embodiments, the methods and devices of the 
present invention can be configured to (a) identify the 
presence of and/or (b) quantitatively estimate or determine 
3o the blood and/or cerebral spinal or intracranial concentration 
level of one or more selected substances in the subject. The 
quantitative assessment can include determining how much 
of the selected substance is crossing the blood brain barrier 
(based on a correlation to the amount present in the selected 
35 region of the eye, typically the AH). In other embodiments, 
the methods and devices of the invention can be used to 
dynamically monitor changes in the operation of the blood 
brain barrier (which may be altered intentionally for some 
embodiments of the invention). 
In any event, generally stated, in operation, a laser exci- 
tation light signal is focused to and transmitted into a 
selected region in the eye. Typically, this will be the AH, but, 
in some embodiments, can also include either the blood 
vessel(s) in the conjunctiva or the vitreous humor. Illumi- 
45 nation of the blood vessel(s) in the conjunctiva of the eye 
will not require as great a penetration depth as either the AH 
or the vitreous humor, while the vitreous humor will require 
the excitation light pulse to have an increased penetration 
depth over that of the AH and the conjunctiva to reach the 
In any event, after the selected region of the eye is 
illuminated, a corresponding Raman spectroscopic signal is 
obtained. Each selected substance can generate a “signature” 
spectrographic signal with different signature peaks at dif- 
5s ferent frequencies. Higher concentrations will yield stronger 
signals. The subject’s spectroscopic signal can then be 
digitally compared to a plurality of reference signals stored 
in computer memory. The reference signals correspond to 
one or more selected substances which can be predetermined 
60 from an in vitro analysis of the substance as it exists in a 
corresponding sample.  For example,  for the AH 
measurement, a representative eye AH can be a representa- 
tive target phantom such as in artificial AH’S, or test vials 
with known concentrations of the substance in a known 
65 solvent, such as a water based or saline solution. 
In certain embodiments, the actual signal of the subject 
can then be compared to the stored “signature” profiles or 
10 
40 
so vitreous humor in the eye. 
US 6,574,501 B2 
15 16 
signals of Raman data corresponding to predetermined sub- 
stances or analytes to identify the presence of one or a 
plurality of the selected substances and/or to estimate or 
quantitatively determine the concentration of that sub- 
laser light into the desired region of the eye (such as, in some 
embodiments, to the anterior chamber and the AH). 
shown in FIG, 5,  in certain embodiments, the light 
collected by the objective lens is directed through bolo- 
stance(s) in the subject. Thus, the present invention is 
to assess, non-invasively, at physiologic levels (typically in 
5 graphic notch filters 20, 21 to remove the undesired portion 
of the reflected scattered light, such as the Raleigh scattered the be in the 
micromolar range for certain substances), the presence of 
embodiments, a relative assessment (two or more measure- 
ments Of the subject for Or changes) 
may be Or with the use Of base Or 
reference spectra. The relative assessment can include 
obtaining at least two different Raman spectrum signals of 
the subject, over time, and comparing any shift in peaks, 
and, thus, physiological changes, in the subject at particular 
frequencies. 
As shown in FIG. 5,  in one embodiment of the present 
invention, the system 5 can be described has having a light 
(excitation or illumination) signal generation portion 8 and 2o 
a detection portion 9 (FIG. lob) with a laser 10 and an 
optical system 1 5 ,  along with a fixation target 25. The 
optical system 15x can be broken into an input portion 15xi 
(relays the light to the subject’s eye) and an output portion 
15x0 (relays the reflected light from the subject). As shown 2s 
in FIG. loa, the light signal generation portion 8 includes the 
laser 10, a signal processor 35s, the input optical system 15xi 
which is configured to direct the light signal into a selected 
region in the eye 12 of the subject (whether the conjunctiva 
vessel(s), the AH, or the vitreous humor). The light genera- 30 
tion portion 8 shown also includes a fixation target 25 used 
to help focus the subject’s eye to the light transmission path. 
The target 25 may be configured to extend adjacently above, 
below or about the perimeter of a light exit/entrance 
eye to focus directly at or into the aperture during operation 
or data acquisition. 
but the levels can light. The Raman scattered light passes through these filters 
with minimal attenuation and is focused through a confocal 
10 focal point in the eye are confocal such that light from 
adjacent structures in the eye can be filtered at this aperture. 
The pinhole 22 also serves as the entrance aperture to the 
spectrometer. The spectrometer shown is an imaging spec- 
trograph with a grating 30, lens 31 and a CCD detector array 
A signal processor 35s, or controller which can be pro- 
vided in a computer 35, controls the laser 10, the fixation 
target and readout display 25, and receives data from the 
CCD detector 32. The architecture of the spectrometer 
shown in the figures is merely one example of devices that 
are suitable for this application. Many types of spectro- 
graphs can be utilized including Fourier transform 
spectrographs, spectrographs using liquid crystal tunable 
filters or other tunable elements. Information can be trans- 
mitted to a remote source such as a computer, database, 
remote physician or the like via modem or other connection 
through a suitable communication link 36 via a wireless link 
or a computer network such including an intranet or a global 
computer network link such as an internet link (such as the 
world wide web), etc. 
In certain embodiments, the CCD detector 32 in the 
spectrometer is of a red-shifted, back-thinned, thick epitaxial 
design such that its sensitivity is optimal in the 700-1100 
detectors may be 
substances in the body Of the subject. In Other pinhole aperture 22 by lenses 23, 24, The pinhole and the 
15 32. 
aperture, preferably proximate to the aperture to allow the 3s nanometer region. Other types Of sensitive 
as 
As noted above, a signal processor 32s such as a digital 
As shown in FIG. lob, the system 5 also includes the 
detection portion 9 which receives the light as it exits the 
associated therewith. The detection portion 9 can include the 
processor in a general PUTose Or purpose 
computer Processes the output of the detector 32. The signal 
laser beam frequency and the power Or intensity Of the laser 
selected region of the eye and detects the Raman spectrum 40 processor Or computer Or Other 
output optical system 15x0 (which may share some of the pulse from the laser Source lo. 
optical components used in the input optical system 15xi), In some embodiments, the signal processor 32s, 
and a spectrometer 32s with a detector 32, and a signal computer, or controller can switch the frequency of the laser 
processor 35s. The signal processor 35s is typically the same 45 to Permit subtraction of fluorescence as described Previ- 
in the transmission and detection portions 8, 9 of the system ously. The signal Processor Or computer can also direct 
5 .  information to a digital display imaged onto the retina. The 
A schematic diagram of one embodiment of the system 5 patient can then read the results of the analysis on this 
is shown in FIG, 5 ,  certain embodiments, in operation, a display. For certain embodiments, the results can be dis- 
tunable, narrow-band laser beam from laser 10 is focused 50 played on the exterior of the device so that a clinician or 
into the anterior chamber 11 of the eye 12 through an police of€icer (the latter being particularly directed for nar- 
objective or ocular lens 13 via lens 15 and filter 16, beam cotics or blood alcohol evaluations) can easily read same. 
splitter 17, and filter 20, certain embodiments, a non- Further, the data or results can be date and time coded and 
fluorescing objective lens with suitable numerical aperture digitally stored and Printed as a medical Or Police record. 
(e.g. 0.24.5) can be used such that Raman scattering from ss As shown in FIG. 6, fibers 40,41 may be used to deliver 
the selected region (i.e., the aqueous humor) is maximized the laser beam and collect the Raman scattered light. In 
while scattering from adjacent structures (e.g., lens, cornea, certain embodiments, the confocal aperture is a circular 
and iris) is reduced. The objective lens can be configured aperture 42 placed on the end of a multimode fiber. As with 
can the 
with respect to the eye so that it has adequate working the pinhole aperture shown in FIG. 5,  the end of the fiber can 
distance to permit focusing of the laser into the selected 60 be placed SO that it is confocal with the objective lens’ focal 
region of the eye (for the AH, the middle of the anterior point in the anterior chamber of the eye. A single mode fiber 
of the cornea. integrated fixation target projected from chamber of the eye. This single mode fiber can help facilitate 
display Screen 25 can be projected via lens 26 through the a diffraction limited spot size at the focal point of the 
same objective lens as the laser, but is focused on the retina 6s objective. 
of the eye. Focusing this fixation target on the retina Afiber delivery and collection system like that depicted in 
simultaneously can control direction and focusing of the FIG. 6 can be connected to alternative detection systems, 
chamber of the eye) without direct contact with or touching can be used to direct the laser beam into the anterior 
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one of which is shown in FIGS. 7a-b. This alternative of the subject). In the embodiment of FIGS. 5-7, a display 
detection system can allow for subtraction of the fluores- screen such as a liquid crystal display is employed. As 
cence spectrum as well as selected sampling of the frequen- shown in FIG. 8, a blinking fixation target in the form of an 
cies most important for calculation of glucose concentration. hourglass 70 can be displayed, focused on the retina, during 
Such an alternative detection system may decrease the size s acquisition of the spectra by the apparatus. Other fixation 
and cost of the instrument. The system depicted in FIG. 7 target forms can also be used such as text, letters, numbers, 
uses one or more fixed frequency or tunable lasers to or other recognizable shapes or objects. This can help 
illuminate the aqueous humor of the eye using the optical optimize the Raman signal from the aqueous humor and 
delivery system shown in FIG. 6. reduce light exposure to other structures of the eye. The 
FIG. 7a illustrates that each spectral feature 50a, 50b, 50c 10 fixation target can be active during the time that the laser 
of the Raman scattered light is related to the excitation beam is active and illuminating the subject's eye. 
wavelength by a fixed offset, usually expressed in wave- As shown in FIG. 9, in some embodiments, a visible 
numbers. Changing the excitation wavelength causes the indication of the results of the test in the form of alphanu- 
Raman spectra to shift in wavelength, as depicted by the meric indicia 71 (or other suitable form, such as a graphical 
different feature or portion of the signal, captured in detector 15 display) can be displayed on the same screen immediately 
range window AA 51 (a relatively narrow band of the signal after the acquisition step (or to a remote or externally visible 
such as about 10 nm) based on Raman spectra 52 for screen for other embodiments). The indicia of FIG. 9 pro- 
excitation frequency LAl as compared to Raman spectra 53 vides a readout for all of the principal Raman-active com- 
for excitation frequency LA2. pounds of the aqueous humor, but the display can be of a 
apparatus that takes advantage of the foregoing is 20 targeted compound of interest (filtered from the overall 
schematically illustrated in FIG. 7b. Like components to spectra) CorresPonding to one Or more, of a desired concen- 
FIGS, 5 and 6 are assigned like numbers, L~~~~ drivers tration level of a selected substance (such as alcohol) as 
and/or tuning electronics 60 are operatively associated with desired. 
a tunable laser or a plurality of fixed wavelength lasers 61, In some embodiments, a motion sensor can be incorpo- 
62, 63. A series of one or more bandpass filteddetector 25 rated into the device so that the test can be aborted upon 
elements 65, 66, 67 operatively associated with amplifiers movement of the eye away from the focal point or so that a 
and an analog to digital converter 68 is used to sample the clinician is alerted as to the movement. For example, upon 
spectrum of the collected light. The center wavelength and transmission of the laser pulse to the selected region in the 
bandwidth of each filter may be chosen to correspond with eye, a sensor can be concurrently operated and used to detect 
a different Raman spectral peak of aqueous humor important 30 movement of the retina away from the target focal point. 
for quantification of the selected substance (such as alcohol, The excitation laser light source can be any suitable laser 
an illegal narcotic or banned substance, a Poison, or beam source which can generate a suitable laser beam signal 
glucose). If this laser is tunable Over about a nanometer Or at a desired frequency output. A distributed feedback laser 
spectrum may be Possible as discussed earlier. Using a laser 35 fixed frequency lasers can be combined with bandpass filters 
with a wider tuning range can allow the Raman shifted (Puppels et al., Applied Spectroscopy 47, 1256-67 (1993)) 
spectra to be SCanned Or slid across a smaller mmber of that can generate pulses for Raman scattering at wavelengths 
bandpass filteddetectors. Since semiconductor lasers with 
extremely wide tuning ranges are not commercially readily 4o (this can reduce the cost and size of the instrument compared 
available, one may instead use a set of narrowly tunable 
lasers each with a different center wavelength as the laser The laser beam can be pulsed from the generator or from 
means in conjunction with a series of bandpass filter/ 
detectors for this purpose. Other suitable light sources can or energy to the tissue in the eye, ne power ofthe excitation 
also be used. 45 laser beam pulse should be sufficiently low to avoid tissue 
Advantageously, the systems described herein may be toxicity, but sufficiently high to provide a measurable Raman 
configured SO that optical components need not and do not signal from the aqueous humor. In general, the laser beam 
contact the cornea of the eye during use, which many pulse will be at a wavelength of from 600 to 900 nanometers. 
patients find objectionable (e.& by providing a suitable In some embodiments, the laser wavelength can be a wave- 
monocular eye CUP for contacting the orbit around the eye). length of 780 to 860 nanometers to reduce fluorescence, 
spectrometer base unit attached by a fiberoptic cable to an eye. In other embodiments, the wavelength can be generated 
ocular probe, or as a single integrated unit including at a lower wavelength, such as between 600-700 
foreoptics, spectrometer, detector, computer and display. nanometers, so as to increase the signal to noise ratio of the 
The apparatus can be configured as a relatively lightweight 55 signal and/or to decrease the power level of the signal in the 
and portable device. In some embodiments, the optics and eye. 
laser source can all be configured to be held in a housing The duration of the pulse will typically be from 1 to 60 
which can be mounted on the user as a headset, or on a seconds in length, and typically be from about 5-20 seconds 
portable platform device similar to vision screening or long. 
vision correction devices used during vision exams. The total energy of the laser pulse transmitted to the eye 
As noted above, a visual fixation target such as a mirror, will typically be between 70-500 milliJoules, with instan- 
LED, or display such as an active liquid crystal matrix taneous power preferably not exceeding about 30-50 milli- 
display or the like can be built into the optical apparatus such Watts. The optical components of the apparatus used to carry 
that it is held in the housing in visual communication with out the method are preferably configured so that energy on 
the patient or user during operation to facilitate focusing of 65 the retina of the eye (as well as other areas susceptible to 
the excitation light into the anterior chamber and maintain tissue toxicity, such as the lens and cornea) transmitted from 
stability of the eye (so that it is properly aligned with the eye the excitation laser beam pulse is not greater than 3000 
SO,  subtraction of the fluorescent components of the acquired can be used to reduce instrument size, Tunable or multiple 
that provide optimum information for multivariate analysis 
to the use of holographic filters or gratings), 
the optical system to provide the desired length and power 
The apparatus of the invention can be implemented as a increase tissue penetration, and reduce phototoxicity to the 
60 
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mW/cm2, more preferably not greater than 100Ck2000 FIG. 11 illustrates method steps for obtaining spectro- 
mW/cm2, and even more preferably, below about 500 graphic readings of the selected region of the eye of a subject 
mW/cm2. according to certain embodiments of the present invention. 
In certain embodiments, a low energy excitation wave can As shown, an excitation or illumination light pulse is trans- 
be used to generate the Raman signal spectrum. “Low 5 mitted to the selected region of the eye of the subject (Block 
energy”, as used herein, means power which is on the order 100). In certain embodiments, this can be carried out by 
of about 1 0 4 0 0  mJ or less, and typically between about positioning a mask-like device over the eyes of the subject 
70-330 mJ. The energy exposure will depend on the power (similar to that used in eye exams) so that (a) the housing of 
and pulse length of the excitation pulse. Longer wavelength the device aligns over the eye socket(s) to seal the eye(s) 
pulses (i.e., above 700 nm) may be used, typically with from ambient lighting, (b) the excitation pulse light is 
energy closer to the higher end of the scale, while lower efficiently directed into the eye (without scattering into the 
wavelengths (600-700 nm) may be able to employ lower environment), (c) and the light reflected from the eye (such 
energy exposure levels. In one embodiment, a wavelength of as the AH) can be captured, but no physical contact with the 
about 633 nm can be used for a Pulse of about 5-10 seconds cornea of the eye itself is required. For example, a monocu- 
corresponding to about a 2 mW Power exposure level and 1s lar eye cup (or binocular eye cups) can be used to contact the 
between a 10-20 mJ energy exposure to the Patient’s eye for orbit around the eye and yet space the optical components 
each measurement or monitoring signal obtained. In other from contacting the cornea, The scattered light from the 
embodiments, an optical excitation pulse may have a 785 nm illumination light pulse is then detected (Block 120). 
length Of about 2o ms and a power rating Of about l5 mW. 2o be focused to a desired location or target spot (Block 105) 
In another embodiment, a set, l6 mW pulse (having a to help direct the excitation light out of and into the eye in 
the in vivo reading of a substance such as a cancer treatment transmission path so that the reflected light is attributed to 
For multiple measurements, the devices may be able to be 2s tiva vessel(s)). In so doing, a manual or autofocusing 
configured to focus on a different eye, alternating the eye to technique can be used. For manual focusing, various meth- 
which the light is transmitted, to reduce the amount of ods can be used to allow the user to adjust the focus. For 
exposure to any one eye. example, a pinwheel can be turned clockwise or counter- 
In certain embodiments, the chemical or analyte concen- clockwise to focus on an object or text or other visual 
tration in the blood can be measured within a 90-99% 30 fixation target to be displayed in the device (typically the 
accuracy level as determined by extracting the aqueous object or text is displayed in a miniaturized display (such as 
humor, putting it in a test tube and measuring the Raman an active matrix display) positioned about the opening 
spectrum. The band of interest is typically in the 200-3200 through which the light is transmitted proximate the light 
cm-1 band. transmission path). For example, LED’s or active matrix 
Any suitable detector 32 can be used to detect a Raman 35 displays can be used to generate text or a blinking or 
spectrum from illuminated aqueous humor. In certain continuous light, which attracts the visual attention of the 
embodiments, a CCD detector or CCD camera can be used subject and which the subject watches or reads during the 
to detect reflective light as they may exhibit increased transmission and detecting steps. 
sensitivity over other types of detectors. The CCD detector Similarly, for autofocusing, the subject can look to the 
preferably is configured to have high quantum efficiency in 40 visual fixation target mounted in the device in visual com- 
the near infrared range. The high quantum efficiency may be munication with the eye. The presentation of the object can 
achieved by any suitable means, such as employing a back be automatically stepped through a visual protocol which 
thinned detector, but one sufficiently thick to reduce etalon can magnify or adjust the visual presentation until the 
effect. subject can read or recognize the object. When this happens, 
The devices of the invention can be operatively associated 45 the reading or recognition indicates that the focus is 
with a patient’s medical equipment such as an insulin pump sufficient, and the reading can be taken (i.e., the transmission 
(for D-glucose) or to a dialysis machine (for urea) by and detection of light). Autofocusing systems with corrected 
wireless or wired electrical or fiber optic lines, radio fre- optic systems are well known to those of skill in the art. For 
quency transmitters and receivers or the like to provide example, optic systems similar to those used to assess vision 
information on the appropriate analyte that can then be used 50 and determine a suitable lens correction for a subject during 
to control that equipment. For example, the reading can be vision examinations can be incorporated into the devices 
used to automatically activate or increase or decrease the according to embodiments of the present invention. 
output of the equipment such as the insulin pump in response Although a contact lens may remain in place during the 
to blood glucose levels, or to regulate the dialysis machine. reading, it is preferred that glasses or other objects which 
In telemedicine applications, the instrument of the inven- ss may physically interfere with the mounting of the device 
tion can be conveniently operatively associated with a over the eyes, be removed during the test. 
remote read-out terminal through a communication link such The power or beam strength of the light pulse can be 
as a telephone, cable, computer, modem, intranet, internet monitored so that fluctuation in the power or strength of the 
connection or other communication line with any suitable light beam which is transmitted to the user can be adjusted 
relay or interconnection means (such as an electrical or fiber 60 so that it the current and/or heat is regulated to be substan- 
optic lines, radio frequency transmitters and receivers, etc.) tially constant (constant current or heat) or numerically 
to provide information on the blood or intracranial (blood- corrected for, typically in the signal processor 35s (Block 
brain fluid) analyte to a remote physician or medical pro- 110). ARaman spectrum of the targeted region of the eye can 
vider (e.g., through a telephone, cable, or wireless connec- then be generated based on the detected and corrected light 
tion to a direct security (for in-home parole) or medical 65 spectroscopic signal (Block 130). Typically, well-known 
monitoring agency or to a selected destination on the statistical correlation or normalization techniques are used to 
intranet, internet, or world wide web). generate the Raman spectrum from the scattered light data 
(Or Other and a pulse During the transmission and detection steps, the eye can 
energy 
agent in the 
level Of about 75 mJ> can be used to Obtain a repeatable and reliable manner (to define a consistent 
proper and reliable illumination of the VH, AH, or conjunc- region Of the eye the AH). 
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received at the detector. See e.g., Standard Practices for theAccuracy ofNIR Spectroscopy with High Levels ofNoise 
Infrared, Multivariate, Quantitative Analysis, ASTM E in the Reference Value, Appl. Spec. 45; 109-115 (1991); 
1655-97; Beebe et al., A n  Introduction to Multivariate Bulmer et al. Factor Analysis as a Complement to Band 
Calibration and Analysis, Anal. Chem. 59, 1007A-10017A Resolution Techniques. I .  The Method and its Application to 
(1987); Draper et al., Applied Regression Analysis (2d ed., s Self-Association ofAceticAcid, J. Phys. Chem. 77; 256-262 
John Wiley and Sons, 1981); Maliowski et al., Factor (1973); Culler et al. Factor Analysis Applied to a Silane 
Analysis in Chemistry (2d ed., John Wiley and Sons, 1991); Coupling Agent on E-Glass Fiber System”, Appl. Spec., 38; 
Mark, H., Principles and Practice of Spectroscopic Cali- 495-500 (1984); Dale et al., Principal Component Analysis 
bration (John Wiley and Sons, 1991); Martens et al., M d -  of diffuse Near-Infrared Reflectance Data From Paper 
tivariate Calibration (John Wiley and Sons, 1989); and i o  Currency, Appl. Spec., 43; 1399-1405 (1989); Gillette et al., 
McClure, G., Ed., Computerized Quantitative Infrared Noise Reduction via Factor Analysis in FT-Zr Spectra, Appl. 
Analysis, ASTM STP 934, ASTM (Philadelphia, 1987). The Spec., 36; 535-539 (1982); Kargacin et al. Ion Intensity and 
contents of these references are hereby incorporated by Image Resolution in Secondary Ion Mass Spectrometry, 
reference as if recited in full herein. Anal. Chem., 58; 2300-2306 (1986); Lindberg et al., Partial 
Thus, any number of suitable computational analysis may is Least Squares Method for Spectrofuorimetric Analysis of 
be used including linear (e.g., algebraic or least squares/ Mixtures of Humic Acid and Ligninsulfonate, Anal. Chem., 
partial least squares) or nonlinear (e.g., artificial neural 55; 643-648 (1983); Lukco et al., The Use of GC-AES 
networks) multivariate analysis techniques, such as, mul- Multielement Simulated Distillation for Petroleum Product 
tiple linear regression (MLR), classical least-squares (CLS, Fingerprinting, J. Chrom. Sci. March, 1993; Malinowski et 
K-matrix), inverse-least-squares (ILS, P-matrix), principal 20 al. Factor Analysis in Chemistry, 2nd edition, John Wiley 
component regression (PCR, PCA, factor analysis), and and Sons, New York, 1991; Malinowski, E. R., Theory of the 
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FIG. 1OC illustrates that the device 5 may include a closed 
loop feedback system 5f for monitoring and regulating the 
strength or intensity of the light excitation beam output to 
a beam splitter positioned to bleed off a portion of the beam 5 light through an eyepiece with a corresponding objective 
and numerical aperture. Marginal rays from this eyepiece are at a location which is proximate to the aperture (the beam outlet port) and substantially continuously detect the beam shown focusing through the cornea and into the aqueous power, intensity, or energy associated therewith to monitor 
the power of the excitation beam as it is transmitted out of humor within the anterior chamber. The confocal optical 
the device, Other embodiments can include dynamically configuration of the instrument allows it to sample Raman 
monitoring the current or power load ofthe laser 10 to adjust lo scattered light in the region near the spot (and sub- 
for temperature or other operational drift or power fluctua- stantially isolated to that region). Thus, in certain 
tion during operation. The signal processor 35s can then embodiments, the optic design can be such that scattering 
adjust the input to the laser as needed and/or store the from the cornea or the intraocular lens can be reduced and 
excitation beam data so that the Raman spectrum can be can be confocally blocked from the instrument’s fiber-optic 
adjusted to reflect the actual beam energy or power trans- 15 entrance aperture within the optical probehead (FIG. lOd, 15 
mitted to the user. probe). 
device with power regulation according to the present inven- by Gullstrand, Gullstrand used special instrumentation to 
tion. As shown, the laser 10 is operably associated with a observe Purkinje reflections from both sides of the cornea 
fiber optic cable 40 which includes or is coupled to a fiber power of the and the intraocular lens into a single 
optic splitter 40s which directs or bleeds a small portion of equivalent lens with node point (N), Based on the knowl- 
into the eye of the patient). Asubstantial portion of the light remains in the primary light transmission path and is 25 one can calculate sizes of objects on the retinal surface. This 
directed into the Raman probe head 15 probe which can, in information can be used to compute the surface area of the 
The R~~~~ spectrometer 32 can be positioned in cornmu- NA=0.25 or NA=0.4 according to certain embodiments of 
In this model, rays passing through (N) can be treated as light upon its return (in the return path). 
As shown, the splitter 40s may split about 1% of the 1f they are unrefracted as they travel through the eye and 
excitation light away from the primary beam to a detection onto the retina. One can construct rays that Pass through (N) 
path 115 and into a photodetector 116 (or other suitable but are also collinear with the eyepieces marginal rays as 
sensor), The photodetector 116 is in electrical communica- shown. A pair of collinear rays entering the lens equivalent 
tion with an AID (analog to digital) converter 118, which 35 model should focus on the retina. Going through this exer- 
converts the corresponding electrical signal so that it can be cise with both Pairs of marginal rays of the eyepiece shows 
digitally input into the processor 35, Thus, the voltage or that one can treat the incident beam as a point source which 
current from the photodetector 116 is measured and digitized emanates from (N) at an angle Bi, the Same angle as the 
(preferably in a substantially continuous or continuous man- marginal rays make with the optical axis. 
ner during operation of the device) and the information 40 As shown in FIG. 20B, simple calculus can be employed 
transmitted to the processor 35 (typically a computer). The to derive an expression for the surface area of a sphere over 
computer or processor 35 can then measure the laser power a solid angle delineated by Bc, the angle of a ray from normal 
and computationally determine a new adjusted current (or that extends to the margins of the surface area exposed on 
voltage) to adjust the laser 10 output to the desired or target the sphere. The expression for surface area is given by 
output value such that it is able to be held to within about 45 equation 1. 
95% of the target output strength. In certain embodiments, 
such as within at least about 98-99%. The computer output 
a human (FIG. 20A). Typically, optical toxicity power 
limitations for the eye are established by regulatory agen- 
cies. 
the eye Of the subject. The feedback system 5fmay FIG, 2OA shows a diagram of the adult eye exposed to 
FIG. 10D illustrates one operational embodiment of a FIG, 20A also shows the nodepoint (N) originally derived 
Power SUPPlY lop. The laser 10 directs the light through a 2o and lens to develop a simple eye model which lumped the 
the light away from the primary light transmission path (and edge of the position of node point (N) relative to the retina, 
operation, be positioned adjacent the eye 12 of the patient. 
nication with the Raman probe so as to be able to detect the 
retina exposed by the 
the 
aperture (NA) (such as 
Of the device and the associated eyepiece). 
30 . 
the output signal strength can be held substantially constant A=2nRZ(1-COS 8J Equation 1 
can be converted back into analog form via a D/A converter 
119 which is used to regulate the voltage power supply lop 
Oi is given as sin-1 Of NA Of the eyepiece) and 
these as not OC, an expression can be derived which 
a function of the radius of the globe and the relative position 
of N given by xo. As shown by equation 2 in FIG. 20B, 
trigonometry can be used to derive this relationship. For any 
Bi, equation 2 can be solved numerically for Bc, using the 
Newton-Rapson method. 
which, in turn, regulates the input to the laser 10. 
The optical system 15xi may also be configured to trans- 
mit the excitation beam such that it presents a wider cone to 
focus to the retina in a manner which is able to cover a larger 
area of the selected region in the eye to thereby operate with 5s 
a lower energyiarea ratio (such as, for at least some AH Equation 2 
applications, configuring the optical system such that the 
numerical apertures of the input optic system 15xi is sub- FIG. 2OC is a graph which plots exposed retinal surface 
stantially matched to the output optic system 15x0 (or area (right vertical axis) and power density assuming a 30 
spectrometer). In certain embodiments, a numerical aperture 60 mW illumination (on the left vertical axis) on the retina as 
of about 0.2-0.5 can be used. The graph in FIG. 2OC shows a function of various eyepiece designs defined by the angle 
a sample power density and exposed retinal area for a of incidence ‘‘Bi”. The line indicated at the angle of inti- 
numerical aperture of 0.25 and a lox objective (Point A) and dence just below 15 degrees (Point A) corresponds to the 
a larger numerical aperture of about a 0.4 (23.6 degrees for numerical aperture 0.25 used for obtaining certain of the 
a 20x objective) at Point B. 65 experimental data shown or described herein. The angle of 
FIGS. 20A-20C illustrate optical power density calcula- incidence associated with a numerical aperture of 0.4 is at 
tions performed using a canonical model of the adult eye of about 23.6 degrees (larger exposed retina area and lower 
R sin 8,=(R cos 8,+xo)tan 8, 
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power density), shown at Point B, used to obtain the data Raman signal of the blood portion and to pursue the Raman 
illustrated in FIGS. 21A-C. This angle can also be expressed signal of plasma (such as by shuttering the beam to discard 
in terms of NAor “f”-number (the focal length divided of the the blood portion or to delay upon detection of signal 
fully illuminated diameter of the limiting aperture). The associated with blood). 
numerical aperture of the entire system places an upper s In certain embodiments, the fluorescence spectrum for the 
bound on the effective numerical aperture. For example, the aqueous humor can be subtracted from the Raman spectrum 
numerical aperture of the embodiment of the device 5 of the by stimulating the aqueous humor with a second excitation 
spectrometer used to determine certain of the described laser light pulse at a wavelength slightly different from that 
results is fi1.8 (NA=0.267). However, the fiber optic cable of the first pulse (e.g., up to two nanometers from the first 
between the spectrometer and the probe head, limits the i o  pulse), and then subtracting one spectrum from the other in 
numerical aperture to fi2.0 (NA=0.24). Thus using an objec- a processor in accordance with conventional techniques. 
tive at a higher f number than the fiber is counterproductive Such techniques are known. See, e.g., Funfschilling and 
since Raman scattered light at the outer angles is not Williams, Applied Spectroscopy 30, 443 (1976); Baraga et 
captured by the fiber. Using the instrument with the same al., Applied Spectroscopy 46, 187 (1992); Wicksted et al., 
incident power but with an objective with an f number is Applied Spectroscopy 49,987 (1995)). In the alternative, the 
smaller than f/2 will generally result in higher power den- fluorescence spectrum can be subtracted out through the use 
sities on the retina with no increase in Raman signal gain. of software or other processing techniques. Thus, the term 
This is because maximum collection efficiency is achieved “subtraction” as used herein is intended to include tech- 
at a particular by matching the f number of the eyepiece to niques such as filtering as well as taking the derivatives of 
that of the system. The present invention can provide 20 the signal. While not essential, other potentially interfering 
designs which can be considered close to optimal, by spectra or signals such as Raman scattering from the lens, 
configuring the system with an f number which is approxi- iris, or cornea can also be filtered or subtracted through a 
mately equal to the eyepiece numerical aperture. Using 30 hardware and/or software processor. Water is typically not 
mW of illumination, one embodiment can provide a lens an issue for Raman spectroscopy, but a water spectrum can 
configuration which exposes about 0.58 cm2 of the retina to zs be subtracted if desired. 
a power density of about 51.5 mW/cm2. For the difference spectrum adjustment embodiments, the 
FIG. 18 illustrates that the illumination target in the eye blood level of the selected substance (or the cerebral spinal 
can be the vitreous humor, a substantially clear gel-like fluid level) for the subject can be determined from the 
region positioned beyond the aqueous humor. The devices difference spectrum by correlating the difference spectrum 
described herein can be configured to operate similarly to 30 to predetermined spectrums or data representing the con- 
that for the AH target, i.e., by transmitting the excitation 
beam to a deeper depth into the eye and into the VH (through 
the lens and/or the portion of the eye accessible when the eye 
is open), illuminating same and then detecting the transmit- 
ted light returned therefrom. The energy levels are prefer- 
ably as noted above for the AH. As the Raman signal from 
VH may exhibit increased fluorescence, signal correction 
(subtraction, differentiation, etc..) may be used to obtain/ 
detect the desired signal data. 
FIG. 19 illustrates that the illumination target in the eye 
can be one or more blood vessels located on the conjunctiva 
at the outer surface of the eye. Using the conjunctiva 
vessel(s) can allow a direct blood level measurement to be 
obtained as this embodiment can focus to the blood flowing 
in the vessel (i.e., the blood itself to directly determine the 
targeted blood level measurement). In operation, the exci- 
tation beam is focused to at least one blood vessel on the 
externally accessible surface of the eye to illuminate the 
blood flowing in the blood vessel (because the blood vessel 
is located on the outer surface of the eve. there is no need to 
centration of a particular substance. 
The computational analysis can use the differential spec- 
trum or the non-differential spectrum depending on the 
desired application (typically associated with the degree of 
3s fluorescence of the selected region of the eye to determine 
the Raman spectrum and identify the presence of any 
selected spectroscopic profile or “signatures” having peaks 
in a spatial region of the spectrum, which, in turn, allows for 
the identification of the presence or concentration of a 
40 selected substance in the selected region of the eye. The 
correlation can be based on an empirically based model, 
formula, or matrix of test data garnered from an actual 
subject or from in vitro samples. The data can be correlated 
and the end results computed in a hardware and/or software 
4s processor. The model can be obtained through linear (e.g., 
partial least squares) or nonlinear (e.g., artificial neural 
networks) multivariate analysis. 
In some embodiments, it can be important that a reference 
set or reference standards of known substances and concen- 
SO trations be aredetermined and stored for comautational 
, l  
illuminate through skin). The targeted blood vessel can be reference. For example, a training set of Raman spectra can 
any of the blood vessels located on or adjacent the conjunc- be used. The training set can include samples from (or 
tiva of the eye (typically these are visually apparent), such representative of)  the selected region of the eye such as the 
as the long ciliary arteries or veins. One suitable target aqueous humor with a broad range of concentrations of the 
location may be one of the blood vessels located outside the ss Raman scattering metabolites. In the training set, the prin- 
iris away form the pupil. The detected Raman spectrum cipal Rarnan-scattering metabolites (or “Raman active 
signal can be analyzed and a direct blood level measurement compounds”) should be provided such that they (for at least 
of the analyte of interest obtained. In certain embodiments, the AH this may include glucose, lactate, urea, ascorbate, 
at least two readings can be taken to obtain data samples at and any exogeneous compounds or drugs present) preferably 
different points of time to watch the spectra change. For 60 do not vary co-linearly with one another among the samples 
example, one can attempt to include data associated with the in the training set. For direct blood measurements (i.e., the 
vessel at a point in time when the blood cells are absent in conjunctiva vessel measurements), the Raman active com- 
the illuminated region in the vessel. Further, the Raman pounds will be those typically present in the blood. The 
signal can be processed (discarded or filtered) to remove the model can be produced with spectra samples obtained from 
data corresponding to red blood cells to enhance the desired 65 one or more prior subjects, with spectra samples obtained 
signal of the analyte of interest (such as glucose). In some from the subject from whom the current blood level of the 
embodiments, the beam can be altered to disregard the analyte of interest is being determined (in which case that 
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subject would be required to provide a blood sample for non-colinearly among the samples. The physiological levels 
determination of the blood concentration of the analyte of of the blood and/or corresponding aqueous humor glucose 
interest), or from test vials or artificial AH’S with known concentration in the test samples can range from 0 or 50 
concentrations of selected metabolites and/or the substance mg/dL to 800 or 1,000 mg/dL, typically including at least a 
of interest. Thus, for an AH-based measurement, a training s 100, 200, 300 or 400 mg/dL difference in concentration 
set can be used, with vials having a plurality of constituents, between the sample with the lowest concentration and the 
those normally present in the eye (including lactate, urea, sample with the highest concentration. 
and ascorbate) and in the substance of interest. Turning now to FIG. 12, one embodiment of the invention 
In some embodiments, to provide an atypical training illustrated therein is particularly suited for the non-invasive 
sample, an artificial cover (such as a contact lens) may be i o  detection, identification and/or measurement of poison in the 
intentionally positioned over the aqueous humor being used blood. A plurality of reference standard spectroscopic spec- 
to generate a sample in a training set. This cover or lens can trum signals are generated (Block 150). The reference 
operate to cause the actual AH to have abnormal levels of signals can be converted into data defining peaks and 
lactic acid (a lactic acid build up) as it is inhibited from frequencies and features of interest and the standards can 
normal operation. is correspond to in vitro samples of a plurality of different 
Typically, the training set uses at least 10, and more selected substances, and in some embodiments, each pre- 
preferably 20, 25, 30 or more Raman spectra samples (and sented at different concentration levels (Block 155). The 
samples of the corresponding blood levels of each of the data associated with the reference standards can be pro- 
selected analytes of interest) with substantial intersample grammed into a computer or signal processor and made 
variability in the levels of the major Raman scattering 20 available for subsequent use. As noted above, the reference 
metabolites (e.g., glucose, ascorbate, lactate, urea, and any standards can correspond to a plurality of different Raman 
drugs, analytes, or exogenous compounds present). The spectrum data corresponding to a plurality of different drugs, 
concentration of the analyte of interest (in either the blood or typical or common poisonous substances. For example, 
or aqueous humor) preferably varies by at least a factor of Raman signatures of the most prevalent chemicals associ- 
2, 5, 10 or 20 or more from the sample with the lowest zs ated with pediatric poison control calls or emergency room 
concentration to the sample with the highest concentration. visits can be analyzed in various concentrations to define an 
This may include providing concentrations of constituents associated Raman signature. These can include common 
less than and greatly above their normal levels such as 0.5 over-the-counter household drugs or medicinal supplies 
times to 15 times the normal levels (for the AH this can such as the drugs identified by brand names acetaminophen, 
include urea, ascorbate, lactate, and, can also include glu- 30 ibuprofen, isopropyl alcohol, methanol, ethylene glycol and 
cose or other substances of interest, in saline). The mixtures the like, or prescription drugs Such as blood pressure 
can be prepared such that they provide a statistically uniform medicines (such as HYTRTN), steroids, antibiotics, birth 
distribution with no biasico-linearity (i.e., 100 different control pills, and the like, as well as household cleaning 
mixtures of four random substances in the test tube). It is chemicals, pesticides, herbicides, and petroleum products. 
anticipated that the calibration curve can be biased to cluster 3s An in situ Raman spectroscopic reading can be obtained 
a training set biased within the normal or low range (i.e., to of the subject (Block 160). The subject may have been 
be skewed, depending on the application). exposed to an unknown poison or substance. In some 
The concentration ratios or correlations may require embodiments, the term “unknown poison or substance” can 
development of the model using subjects with multiple also include an unknown quantity of a known substance. For 
different diseases (e.g., renal failure, diabetes, seizures, 40 example, a guardian acknowledges that a TYLENOL bottle 
mitochondrial myopathies, sickle cell disease, heart failure, was found empty next to a young child, but it is unknown 
blood clots, etc.) and/or other parameters such as gender, how many pills may have been in the bottle. The present 
age, weight, national origin, etc. For human applications, the invention may be able to determine whether a toxic amount 
model may even be determined with spectra samples was consumed. 
obtained from animals, particularly primates. The sample of 4s In any event, the presence (or absence) of at least one 
the selected region in the eye may be a natural sample selected substance in the subject can be identified (Block 
(human or animal), or may be a man-made or surrogate 170). The amount of the identified substance in the selected 
aqueous humor sample created to mimic natural samples, region of the eye of the subject may also be determined. 
where the blood level is calculated from a priori knowledge Based on the amount in the eye, an amount (a) in the blood 
of the relationship between blood levels and aqueous humor SO and/or (b) in the cerebral spinal fluid or intracranial fluid can 
levels for the analyte(s) of interest (for the blood level be established (anticipating that the amount in the AH can be 
measurements). Similarly, for the cerebral spinal or intrac- correlated to either the amount in the blood or the amount in 
ranial fluid, the aqueous humor sample may be a natural the cerebral spinal or intracranial fluid), thus allowing the 
sample (human or animal), or may be a man-made or presence and concentration to be indirectly established or 
surrogate aqueous humor sample created to mimic natural ss estimated based on the detected presence and/or concentra- 
samples, where the level is calculated from a priori knowl- tion in the selected region of the eye (such as the AH) (Block 
edge of the relationship between cerebral spinal or intrac- 180). Physiological differences among different population 
ranial levels and aqueous humor levels for the analyte(s) of segments may require determination of different correlation 
interest. factors for each population segment (segmented by selected 
For example, when the analyte of interest is glucose, the 60 parameters of interest such as by age, gender, national 
training set of samples for the empirical model can comprise origin, etc.) 
at least 20, 25 or 30 aqueous humor spectra samples. The In one embodiment, a Raman spectraispectrum poison 
samples can include varying levels of constituents which control substance identification database can be generated 
correspond to measured blood glucose levels, where the and the in situ reading then compared thereto so that a 
principal Raman active compounds in the aqueous humor 65 screening and assessment of the identity of which poison or 
samples (glucose, ascorbate, lactate, urea, and preferably poisons that the subject has been exposed can be readily 
any exogenous compounds such as drugs) vary substantially identified by matching the in situ reading to one or more of 
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the pre-determined and digitally stored Raman spectra. The aqueous humor in the anterior chamber is illuminated (Block 
database of selected substances may be held on a central 260); (c) detecting a Raman spectrum corresponding to the 
database which can be remotely located or located at illuminated aqueous humor (Block 270); and (d) monitoring 
regional or selected locations (via the internet, intranet, or the blood brain barrier dynamics based on the detecting step 
other communication means) and the localized reading can s (Block 280). The method may also include the step of 
be uplinked to the larger database for a more comprehensive exposing the subject to selected conditions during the focus- 
screening. Alternatively, the signal processor or computer ing and detecting steps (Block 275). 
associated with the Raman excitationidetection device or In certain embodiments, the monitoring step can be used 
system may be configured with data corresponding to the to assess whether the dynamics thereof alter sufficiently to 
most common types of substances and if a localized scan i o  allow selected analytes, which would normally be inhibited 
fails to match the in situ reading, a more comprehensive 
computational screening can be performed off-line or at the 
remote or larger database location. 
As shown in FIG. 13, another embodiment of the present 
invention is directed to an in vivo method for monitoring the 
administration of a targeted therapy such as a drug, 
chemical, gene, or other therapy, given to a subject for 
treatment of a condition in the brain (such as various cancers 
or neurologic conditions). For example, the present inven- 
tion may be used during a treatment session using delivery 
from traveling through the blood brain barrier, to pass into 
the intracranial spinal fluid through the blood brain barrier. 
This can be useful for clinical trials or assessments of new 
drugs or treatment therapies. In other embodiments, the 
is monitoring step can be carried out when a person is under or 
exposed to extreme conditions such as when diving, flying, 
or mountain climbing, or when suffering from a traumatic 
head or brain injury, high stress, or the like. 
The method can also include the steps of comparing the 
20 Raman spectrum from the detecting step to reference spec- 
of a cytotoxic agent to treat a cancerous tumor in the brain trums corresponding to at least one selected analyte of 
(or to other patients for specialized drug treatments targeted interest, and indirectly identifying the presence of the least 
to the brain such as for treating neurological impairments in one analyte of interest in the subject’s cerebral spinal fluid 
the brain). The method includes administering a dose of a based on the detecting and comparing steps. 
selected treatment agent (typically chemotherapy) to a sub- zs FIG. 15 illustrates yet another embodiment of the present 
ject (Block 200). The dynamics of the blood brain barrier are invention. This method for identifying an alteration in the 
deliberately or intentionally altered from the normal state blood brain barrier of a biological subject comprises the 
(Block 210). The dynamics or functionioperation of the steps of  (a) non-invasively obtaining a first in vivo Raman 
blood brain barrier are monitored by non-invasively obtain- spectrum of the aqueous humor of the subject (Block 300); 
ing the Raman spectrum of the aqueous humor (Block 220). 30 (b) non-invasively obtaining a second in vivo Raman spec- 
A physiologically suitable non-specific marker, selected for trum of the aqueous humor of the subject (Block 310); (c) 
its normal reluctance to cross the blood brain barrier, can be comparing the first and second readings (Block 320); and (d) 
administered to the subject (Block 225), and the monitoring detecting an alteration in the blood brain barrier by com- 
step can be carried out by identifying its presence in the paring the first and second Raman spectrums (Block 330). 
selected region of the eye (typically in the AH, but the 3s In another embodiment, shown in FIG. 16, a method for 
vitreous humor or “VH’ may also be suitable in certain identifying an alteration in the blood brain barrier of a 
embodiments). The non-specific marker can be synthetic or biological subject comprises the steps of  (a) non-invasively 
natural as noted (such as an antibiotic or conjugated billiru- obtaining a first in vivo Raman spectrum of the AH of the 
bin or other suitable analyte). subject (Block 350); (b) obtaining a reference spectrum of 
The dose of the (chemotherapeutic) agent delivered to the 40 an in vitro sample representing the aqueous humor and 
brain can be estimated by determining the concentration in comprising at least one selected analyte (Block 360); and (c) 
the AH (Block 230). The monitoring step can optionally be comparing the in vivo Raman spectrum to the reference 
repeated a plurality of times during the administering step spectrum to identify an abnormality in the blood brain 
(Block 235). The blood brain barrier can be returned sub- barrier (Block 370). The abnormality may be indicated by 
stantially to its normal state after a sufficient quantity of 4s detecting in the AH the presence of at least one selected 
(chemotherapeutic) agent has been delivered to the brain analyte (typically one which is normally inhibited from 
(Block 240). The altering step can be carried out by admin- passing through the blood brain barrier because of its 
istering a chemical which can be flushed from the system or molecular size or permeability and, as such, is not normally 
the dosing terminated to allow the normal function to return. present in the intracranial fluid) thereby its presence in the 
In some embodiments, the non-specific marker can be the SO AH also indicates its presence in the intracranial fluid of the 
therapeutic agent itself. subject. 
In one embodiment, the altering step is carried out by The at least one selected analyte can be one which 
introducing an osmotic agent or chemical (such as a drug typically does not cross the blood brain barrier so that a 
identified by a trade name of MANATOL) to the subject to determination of its presence in the sample is indicative of 
temporarily open the blood brain barrier to allow larger ss an abnormality or impairment or successful intentional 
molecules to pass therethrough. In another embodiment, the alteration of the blood brain barrier dynamics. In one 
altering step can be carried out by increasing the intracranial embodiment, the at least one selected analyte can be a 
pressure of the subject (such as by positioning the subject in bacteria. 
a pressurized chamber). FIG. 17 illustrates an additional embodiment of the 
Another embodiment is shown in FIG. 14. This embodi- 60 present invention. In this embodiment, a reference library of 
ment is directed to a method of non-invasively monitoring the profiles of the chemical peaks (chemical peak profiles 
the operationifunction of the blood brain barrier (which can can also include the chemical valleys or line shapes) of the 
include detecting any change from a normal state). The Raman spectra signals of a plurality of substances can be 
method comprises the steps of  (a) generating an excitation established or generated (Block 400). This can include 
beam at a wavelength of from 600 to 900 nanometers (Block 65 providing the chemical peak profiles for each of the plurality 
250); (b) focusing the excitation beam of said generating of the substances at different concentrations. A Raman 
step into the anterior chamber of an eye of the subject so that spectrum signal can be obtained in vivo of the AH (or VH) 
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of the eye of a subject (Block 410). The chemical peak and partly on a remote computer or entirely on the remote 
profile of the in vivo obtained Raman signal can be deter- computer. In the latter scenario, the remote computer may be 
mined (Block 420). Next, the profile of the in vivo data is connected to the user’s computer through a local area 
compared to the reference library to see if there is a network (LAN) or a wide area network (WAN), or the 
statistical correlation (or best fit match) between one or more s connection may be made to an external computer (for 
of the library profiles with the in vivo obtained profile example, through the Internet using an Internet Service 
(Block 430). If the answer is yes, then a list of one or more Provider). 
substances can be generated with a percent correlation of the The present invention is described herein with reference 
likelihood of the match (Block 440). The method may also to flowchart illustrations and/or block diagrams of methods, 
rule out potential suspects (Block 441). The list is likely to i o  apparatus (systems) and computer program products accord- 
include one or more substances, as many will contain ing to embodiments of the invention. It will be understood 
chemicals with overlapping peaks, but the presence or that each block of the flowchart illustrations and/or block 
absence of other peaks can help statistically fit the data to diagrams, and combinations of blocks in the flowchart 
identify the closest matches. If there is no match, or the illustrations and/or block diagrams, can be implemented by 
correlation percentage is below a certain threshold (such as is computer program instructions. These computer program 
below 20-50%), then the test can be identified as inconclu- instructions may be provided to a processor of a general 
sive (Block 450). The method may also allow a physician to purpose computer, special purpose computer, embedded 
query whether as suspect drug or substance is indicated, processor or other programmable data processing apparatus 
which may for example, consider whether a particular to produce a machine, such that the instructions, which 
“suspect” substance which is believed to be the ingested or 20 execute via the processor of the computer or other program- 
consumed poison may be in the subject. In turn, the method mable data processing apparatus, create means for imple- 
can respond to the inquiry to exclude the substance as a menting the functions specified in the flowchart and/or block 
suspect with an identified statistical percentage (i.e., 95% diagram block or blocks. 
confidence level that substance is not methanol) or to These computer program instructions may also be stored 
otherwise note the probability of this as the poison (i.e., 5% zs in a computer-readable memory that can direct a computer 
probability that the substance is methanol). or other programmable data processing apparatus to function 
As will be appreciated by one of skill in the art, the in a particular manner, such that the instructions stored in the 
present invention may be embodied as a device, method, or computer-readable memory produce an article of manufac- 
system comprising a digital processing system, and/or com- ture or output a test result including instruction means which 
puter program product. Accordingly, the present invention 30 implement the function specified in the flowchart and/or 
may take the form of an entirely hardware embodiment or an block diagram block or blocks. 
embodiment combining software and hardware aspects. The computer program instructions may also be loaded 
Furthermore, the present invention may include a computer onto a computer or other programmable data processing 
program product on a computer-usable storage medium apparatus to cause a series of operational steps to be per- 
having computer-usable program code means embodied in 3s formed on the computer or other programmable apparatus to 
the medium. Any suitable computer readable medium may produce a computer implemented process such that the 
be utilized including hard disks, CD-ROMs, optical storage instructions which execute on the computer or other pro- 
devices, or magnetic storage devices. grammable apparatus provide steps for implementing the 
The computer-usable or computer-readable medium may functions specified in the flowchart and/or block diagram 
be or include, for example, but not limited to, an electronic, 40 block or blocks. 
magnetic, optical, electromagnetic, infrared, or semiconduc- As is seen in FIGS. loa, b, c, FIGS. 5 and 6, the system 
tor system, apparatus, device, or propagation medium. More 5 includes a signal processor or controller 32s. The signal 
10 specific examples (a non-exhaustive list) of the processor or controller can be a general purpose 
computer-readable medium would include the following: an microprocessor, a digital signal processor or a specific 
electrical connection having one or more wires, a portable 4s purpose processor. The signal processor can be an electronic 
computer diskette, a random access memory (RAM), a device, a software or program-implemented device running 
read-only memory (ROM), an erasable programmable read- on a general-purpose computer, or combinations of such. 
only memory (EPROM or Flash memory), an optical fiber, The present invention should not be construed as limited to 
and a portable compact disc read-only memory (CD-ROM), the particular configurations illustrated in the figures but is 
a CD ROM, a DVD (digital video disk), or other electronic SO intended to encompass other configurations capable of car- 
storage medium. Note that the computer-usable or rying out the operations and/or functions described herein. 
computer-readable medium could even be paper or another The signal processor 32s can be any commercially avail- 
suitable medium upon which the program is printed, as the able or custom microprocessor. The computer 32 or signal 
program can be electronically captured, via, for instance, processor or controller may include a data processing system 
optical scanning of the paper or other medium, then ss with I/O data port(s) or other such devices that also com- 
compiled, interpreted or otherwise processed in a suitable municate with the processor. The I/O data port can be used 
manner if necessary, and then stored in a computer memory. to transfer information between the data processing system 
Computer program code for carrying out operations of the or signal processor 32s and another computer system or a 
present invention may be written in an object oriented network (e.g., the Internet) or to other devices controlled by 
programming language such as Java@, Smalltalk or C++. 60 the processor. These components may be conventional com- 
However, the computer program code for carrying out ponents such as those used in many conventional data 
operations of the present invention may also be written in processing systems which may be configured in accordance 
conventional procedural programming languages, such as with the present invention to operate as described herein. 
the “C” or FORTRAN programming language or even The devices or the present invention may include memory 
assembly language. The program code may execute entirely 65 devices containing the software and data used to implement 
on the user’s computer, partly on the user’s computer, as a the functionality of the data processing system or signal 
stand-alone software package, partly on the user’s computer processor 32s. The memory can include both programmable 
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and read-only memory. Typical programmable memory 
includes, but is not limited to static RAM (SRAM), dynamic 
RAM (DRAM), flash RAM, EEPROM or other such pro- 
grammable memory devices whose contents may be modi- 
fied. The read only memory may be of a type which may not 
be modified after its initial programming, such as ROM or 
PROM but may also be programmable in certain embodi- 
ments of the present invention. 
The memory may contain several categories of software 
and data used in the data processing system or system 
processor: the operating system; the inputioutput (IiO) 
device drivers; and the image (and/or in the case of dual 
stimulus, the auditory) data. As will be appreciated by those 
of skill in the art, the operating system may be any operating 
system suitable for use with a data processing system, such 
as OSi2, AIX or OW390 from International Business 
Machines Corporation, Annonk, N.Y., WindowsCE, 
WindowsNT, Windows95, Windows98 or Windows2000 
from Microsoft Corporation, Redmond, Wash., PalmOS 
from Palm, Inc., MacOS from Apple Computer, UNIX or 
Linux, proprietary operating systems or dedicated operating 
systems, for example, for embedded data processing sys- 
tems. 
The I/O device drivers typically include software routines 
accessed through the operating system to communicate with 
devices such as the input devices, the display 25 (FIG. 7), the 
I/O data port(s), and certain components of the memory. The 
data can be static and dynamic data used by the operating 
system, I/O device drivers, the detector, and other software 
programs that may reside in the memory. 
While the present invention is described, for example, 
with reference to particular divisions of programs, functions 
and memories, the present invention should not be construed 
as limited to such logical divisions. Thus, the present inven- 
tion should not be construed as limited thereto as it is 
intended to encompass any configuration capable of carrying 
out the operations described herein. 
The present invention is explained in greater detail in the 
following non-limiting Examples, in which “pL” means 
microliters; “dL” means deciliters, “mW’ means milliwatts, 
“nm” means nanometers, “Kg” means kilograms, “J” means 
Joules, “cm’” means square centimeters, and temperatures 
are given in degrees Centigrade. 
EXAMPLE 1 
Measurement of Aqueous Humor Glucose In Vitro 
with Raman Spectroscopy 
Aqueous humor was obtained from sixteen New Zealand 
white rabbits within one minute of sacrifice by other inves- 
tigators. These animals had experienced experimental myo- 
cardial infarction 48 hours prior to euthanasia. They were 
sacrificed by rapid exsanguination under ketamine and xyla- 
zine anesthesia. Aqueous humor samples were kept frozen 
until glucose levels could be measured and Raman spec- 
troscopy performed. Glucose concentration was measured 
with a commercial glucometer (Glucometer Elite, Bayer, 
Elkhart, Ind., USA) and confirmed against concentration 
standards. Each measurement was repeated, and the average 
measurement was considered actual glucose concentration. 
Samples were placed in conical quartz cuvettes designed 
to hold a volume of 80 pL and permit direct optical access 
to the solution by the spectrometer without traversing glass 
walls or coverslips. 
Raman spectroscopy was performed with a fi1.8 holo- 
graphic imaging spectrograph (Kaiser Optical Systems, Ann 
Arbor, Mich., USA) attached to an Olympus Bx60 micro- 
scope with lox  objective. Data were collected using a 
Princeton Instruments (Trenton, N.J., USA) camera with a 
1024x256 CCD array (EEV, United Kingdom) cooled to 
-80” C. with liquid nitrogen. Illumination of the sample 
s through the microscope objective was achieved with a 
Ti:Sapphire laser (Spectra Physics 3900S, Mountain View, 
Calif., USA) pumped by an argon laser (Spectra Physics 
2010E). Spectrographic data was integrated while the 
sample was illuminated at a wavelength of 785.0 nm (30 
i o  mW) for 10 seconds. This illumination was then repeated at 
a wavelength of 787.2 nm. 
The integrated spectra at the two slightly different wave- 
lengths were then subtracted from one another. This effec- 
tively eliminates the broadband fluorescence, which does 
15 not shift relative to the excitation wavelength. It leaves the 
Raman-shifted spectra appearing as a bipolar pattern (FIG. 
Multivariate analysis of the spectra was accomplished 
using Holograms (Princeton Instruments, Trenton, N.J.) and 
2o Grams (Galactic Industries, Salem, N.H. USA) software 
packages. Thirty-two aqueous humor samples (from sixteen 
rabbits) were evaluated using a “round robin” approach to 
iteratively group all but one of the samples into a training 
set. Hence, the system trains on all but one of the samples, 
2s estimates the glucose level in that sample, then rotates the 
test sample into the training set. This cycle is repeated until 
all samples have served as an unknown test sample. 
A back propagation neural network (D. Rumelhart et al., 
3o Nature 323, 533 (1986))was employed to determine if a 
nonlinear regression method would better predict the glu- 
cose concentration from the Raman spectra of aqueous 
humor. Such a model may compensate for as yet unknown 
interactions between analytes in aqueous humor. A two-layer 
3s back propagation neural network (Neuralware, Inc., 
Pittsburgh, Penn., USA) was employed using a sigmoidal 
function as the nonlinear element. Factors derived from the 
partial least squares algorithm served as the inputs to the 
neural network. Raw spectral data could have been used but 
4o would have required a prohibitively large training set. As in 
the linear regression preformed earlier, round robin training 
and testing was utilized. During training, the neural net- 
work’s weights were adjusted to minimize the total squared 
error between the actual glucose concentration and the 
4s predicted glucose concentrations. Each sample was tested 
using a neural network trained on the remaining 31 samples. 
EXAMPLE 2 
1). 
Correlation of Aqueous Humor Glucose with 
so Rising Blood Glucose 
Nine female New Zealand white rabbits were used for this 
part of the study. They were anesthetized with ketamine (50 
mg/kg) and xylazine (7.5 m a g )  given as a single intra- 
5s muscular injection. Xylazine blocks release of insulin from 
the pancreas and causes blood glucose to rise (K. Chalabi et 
al., Ophthalmic Res. 19, 289 (1987); J. Arnbjerg et al., 
Ophthalmic Res. 22, 265 (1990)). 
Blood samples were taken from the central ear arteries at 
60 various times following the injection of anesthetic once the 
animals were adequately anesthetized. Whole blood was 
immediately measured for glucose concentration with a 
commercial glucometer (Glucometer Elite, Bayer). In most 
instances two measurements were made. The average mea- 
65 surements are reported. If the measurements differed by 
more than 20%, a third measurement was made. If one 
measurement differed by more than 20% from the mean, it 
US 6,574,501 B2 
35 
was discarded. In instances when blood glucose concentra- 
tion appeared stable, occasionally only one measurement 
was made. 
At various times after induction of anesthesia, samples of 
aqueous humor were taken. This was done by paracentesis 
with a 25-gauge needle through clear cornea near the limbus 
after administration of proparacaine eye drops. Aqueous 
humor glucose concentration was measured with the glu- 
cometer in a manner similar to the blood. 
In rabbits, there is massive breakdown of the blood- 
aqueous barrier after a single paracentesis of the anterior 
chamber of the eye (W. Unger et al., Exp. Eye Res. 20,255 
(1975)). The aqueous humor becomes too viscous for repeat 
paracentesis for at least 30 minutes. Consequently, the 
results are reported for the first paracentesis of an eye. In a 
few instances, however, a second paracentesis was made an 
hour later to assess how the breakdown of the blood-aqueous 
barrier may have affected the correlation of aqueous glucose 
with plasma glucose. 
Average blood glucose concentrations for each animal 
were plotted against time after anesthetic injection. Since it 
was not possible to obtain blood samples simultaneous with 
aqueous humor samples, a best-fit second-order polynomial 
was calculated for each animal. This was used to calculate 
the blood glucose concentration at the time that the aqueous 
humor sample was taken. Aqueous humor glucose concen- 
tration was then plotted against the calculated simultaneous 
blood glucose concentration for all animals. DeltaGraph 
software (Delta Point, Inc., Monterey, Calif. USA) was used 
for all statistical calculations. 
EXAMPLE 3 
Results for Measurement of Aqueous Humor 
Glucose In Vitro with Raman Spectroscopy 
The raw spectra of rabbit aqueous humor show broad 
fluorescence peaks that obscure the underlying Raman sig- 
nature (FIG. 1). When the spectra from the two slightly 
different wavelengths are subtracted, one from the other, the 
Raman shifted spectra become apparent as bipolar peaks. 
Actual aqueous humor glucose concentration, measured 
by the glucometer, ranged from 37 to 323 mg/dL in the 
thirty-two samples. Multivariate analysis of the raw spectra 
from these samples with the partial least squares algorithm 
revealed fair correlation (r2=0.76) between the predicted 
aqueous humor glucose concentration and the actual con- 
centration. Multivariate analysis of the subtracted spectra 
from these samples with the partial least squares algorithm 
resulted in improved correlation (r2=0.90) between the pre- 
dicted aqueous humor glucose concentration and the actual 
concentration. When back propagation with an artificial 
neural network is further applied to the data, correlation is 
excellent (r2=0.98) (FIG. 2). 
EXAMPLE 4 
Results for Correlation of Aqueous Humor Glucose 
with Rising Blood Glucose 
The rate of rise of blood glucose after xylazine injection 
is highly variable from animal to animal (FIG. 3). In fact, in 
one rabbit there was little change in the blood glucose 
concentration over time. 
If only samples taken in the first fifteen minutes after 
anesthetic injection are considered, aqueous humor glucose 
concentration is higher than blood glucose concentration 
(207228 mg/dL for aqueous humor; 135227 mg/dL for 
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blood). When calculated blood glucose rises above 200 
mg/dL, simultaneous aqueous humor glucose parallels blood 
glucose nearly linearly [aqueous humor glucose=1.18 (blood 
glucose)-72.7; r2=0.88] (FIG. 4). 
The number of aqueous humor samples from second 
paracenteses was insufficient to draw conclusions about their 
significance. They did not appear, however, to correlate well 
with aqueous humor glucose levels from initial paracenteses 
(FIG. 4). 
These data indicate that the baseline ratio of aqueous 
humor glucose to blood glucose in rabbits is approximately 
1.5. (It may actually be higher than this as a true baseline 
was not obtained, and the blood glucose levels were likely 
elevated by the time the first samples were obtained, even in 
the first 15 minutes after injection.) This is much higher than 
in humans and higher than in previous reports on rabbits. All 
previous reports on rabbits, however, were prior to recog- 
nition of the hyperglycemic effect of xylazine anesthesia, yet 
many of them used xylazine anesthesia. In addition, most 
previous reports assumed that the rabbits were at steady- 
state euglycemia, without actually confirming that this was 
the case. These facts may account for some of the highly 
variable results in previous reports. 
These data also demonstrate that aqueous humor glucose 
25 in the rabbit responds almost immediately once blood glu- 
cose exceeds 200 mg/dL. The relationship of aqueous humor 
glucose to blood glucose is nearly linear while blood glucose 
is rising above 200 mg/dL. Below that level, aqueous humor 
glucose appears stable. What happens to aqueous humor 
3o glucose when blood glucose is clamped at a hyperglycemic 
level, or when blood glucose concentration drops, has yet to 
be determined. Nonetheless, equilibration of aqueous humor 
glucose with blood glucose probably occurs within minutes 
in rabbits. If rapid equilibration of aqueous humor glucose 
35 also occurs in humans, it could serve as an excellent 
substrate for non-invasive glucose monitoring. 
Previous investigators have found no breakdown in the 
blood-aqueous barrier of albino rabbits exposed to infrared 
radiation with energy densities up to 106 J/cm (D. Reddy, 
4o supra; G. Peyman et al., Exp. Eye Res. 42, 249 (1986); T. 
Kumik et al., Znv. Ophthalmol. vls. Sci. 30, 717 (1989)). 
Infrared energy densities as low as 44 J/cm2 may be suffi- 
cient to breakdown the blood-aqueous barrier in pigmented 
rabbits, however. This is still substantially higher than the 
45 energy density that would need be applied with the Raman 
technique disclosed herein. 
FIGS. 21A-C illustrate experimental results obtained for 
(a) the spectrum for an artificial in vitro AH in a model 
anterior chamber (FIG. 21A); (b) the spectrum for an actual 
so in vitro measured (extracted real AH) in a model anterior 
chamber (FIG. 21B); and (c) the spectrum for an actual in 
vivo AH measurements (FIG. 21C). A 20x objective with a 
numerical aperture of about 0.4 was used to obtain the data. 
The “ensemble” spectra (of the constituents of the AH) 
55 correspond well between the three figures. As may be 
expected, the in vivo and in vitro intensity of the Raman 
spectra was less than the in vitro artificial sample, but the 
spectra peaks corresponded well between the measurements 
(the device able to detect the physiological levels). The in 
60 vitro measurements of the AH were obtained using extracted 
rabbit eyes placed under a contact lens. 
5 
15 . 
20 
EXAMPLE 5 
Measurement of Integrity of Blood-Aqueous and 
Blood-Brain Barriers 
The blood-brain and blood-aqueous barriers block pas- 
sage of large molecules into the cerebrospinal fluid or 
65 
US 6,574,501 B2 
37 
aqueous humor. Many drugs and disease processes result in 
disruption of both the blood-aqueous barrier and the blood- 
brain barrier. In the case of such drugs or disease processes, 
disruption of the blood-brain barrier can be inferred from 
breakdown of the blood-aqueous barrier. Breakdown of the 
blood-aqueous barrier can be measured by measuring the 
protein content of the aqueous humor or by measuring the 
concentration of other substances (e.g., drugs) within the 
aqueous humor. Such substances may be quantifiable by 
Raman spectroscopy and the protein can be calculated from 
the fluorescence spectrum since the fluorescence spectrum is 
largely generated by protein. Consequently, the devices 
disclosed herein for measuring glucose and other Raman 
scattering metabolites in the eye can be used for measuring 
the integrity of the blood-aqueous and blood-brain barriers. 
Raman scattering molecules of different sizes that do not 
normally cross the blood-aqueous or blood-brain barrier 
could be administered to a patient intravenously. The pres- 
ence of these molecules is then identified and/or quantified 
by Raman spectroscopy of the anterior chamber of the eye. 
This can be used to determine the size of molecules which 
pass through the blood aqueous barrier. The signature of the 
Raman spectroscopy signal can then digitally be compared 
to reference signals (without requiring the use of a difference 
methodology which would subtract the amount of fluores- 
cence to reveal the Raman spectra of these substances) with 
the device disclosed herein would reflect the passage of 
natural proteins through the blood-aqueous and blood brain 
barriers. 
Therapeutic drugs can also be measured to determine their 
effectiveness in crossing the blood-aqueous or blood-brain 
barrier. 
EXAMPLE 6 
Monitoring the Blood Brain Barrier during a 
Treatment Session 
Apatient undergoing treatment for a cancer located in the 
brain or on the other side of the blood brain barrier is 
administered a non-specific marker which is configured such 
that it does not normally cross the blood brain barrier (or is 
reluctant to do so) and which is relatively easily detectable 
when in the AH by the use of Raman spectroscopic analysis. 
The blood brain barrier can be altered by administering an 
osmotic agent such as a chemical substance (such as a drug 
identified by the trade name "MANATOL" or a similar 
substance) which acts to physiologically alter the blood 
brain barrier. In so doing, the blood-aqueous barrier is also 
altered. In turn, the non-specific marker travels to the AH. 
An optical measurement can be obtained to confirm that the 
non-specific marker is indeed in the AH (in a sufficient or 
elevated quantity to indicate that the blood-aqueous barrier 
has been altered). The present invention, recognizing that 
the mechanics of the blood-aqueous barrier and the blood- 
brain barrier are similar, then presumes that the blood brain 
barrier has also been altered sufficiently (scale correlation 
factors may be applied to assure that the blood brain barrier 
is openedialtered a sufficient amount). 
A therapeutic drug (which may be a chemotherapy or 
cytotoxic drug) can then be administered (injected or 0th- 
envise delivered) to the subject. Administering the thera- 
peutic drug after the barrier has been altered can help ensure 
that the therapeutic drug is not introduced until the blood- 
brain barrier is altered sufficiently and can allow an elevated 
amount of the therapeutic drug to pass through the blood- 
brain barrier over a non-altered state. This can facilitate that 
38 
more of the drug goes where it is targeted and can reduce the 
amount in the system of the subject which can often be 
exposed to undesirable amounts of cytotoxic drugs in con- 
ventional treatments in order to ensure that a sufficient 
s amount actually reaches the tumor. 
Thus, the present invention now allows one to intention- 
ally break down the barrier and non-invasively confirm the 
alteration before delivering medicines, which do not nor- 
mally readily cross the blood brain barrier, to tumors and the 
10 like positioned in the blood aqueous or blood brain barrier. 
Correlations of the amount of the drug administered to the 
subject, to the amount of the marker administered and 
detected in the AH, may be established to allow an estimate 
of the amount of the drug in the spinal fluid or in the blood. 
15 Thus, the present invention may also be able to titrate the 
dose so that the levels in the spinal fluid are sufficiently high 
but not toxic to the patient in non-targeted regions of the 
body. 
EXAMPLE 7 
Measurement of Brain Alcohol Level 
A portable device can be used to hold the optical genera- 
tion and measurement system. The device can be readily 
25 carried by police enforcement agencies and conveniently 
used when a suspect is evaluated for potential DUI infrac- 
tions. Thus, the device can be positioned over the eye(s) of 
the subject and the subject can be instructed to read or 
identify the text or object encoded or displayed as the 
3o fixation target in the headset over the eye or eyes. When the 
subject verbally affirms the proper identification of the 
fixation target, the device can be operated to obtain a 
reading. The device may include an auto or manual focus to 
correct the vision in the device and to allow the subject to 
35 focus to the target as needed. Almost instantaneously, the 
police officer can have quantitative results of the brain 
alcohol or blood alcohol level of the suspect. The amount or 
concentration of the alcohol determined to be in the AH (or 
conjunctiva vessel) can be correlated to either a blood 
4o alcohol and/or brain alcohol level. Many states presently 
regulate blood alcohol levels; however, it is anticipated that 
an impairment can be assessed also based on either or both 
blood or brain alcohol levels. As such, the device may 
generate a plurality of numbers, such as the concentration in 
45 the eye, and, the indirectly measured or correlated concen- 
tration in the blood and/or brain. If above the legal limit, 
which can be programmed for each state or locality, a 
documentary arrest record can be generated with a date and 
time stamp encoded onto the measurement record which can 
be automatically generated and electronically stored or 
printed. 
In some embodiments, the Raman spectrum of the subject 
may include many wavelengths and the determination of the 
concentration or presence of alcohol may include determin- 
55 ing the significant peaks associated with alcohol and sub- 
tracting the AH constituents from the signal. It is anticipated 
that the method and devices will be able to identify blood 
alcohol and brain alcohol levels between about 0.001-1%, 
and typically between 0.01-0.8% (noting that concentra- 
6o tions above 1% may be lethal) and that medical assistance 
may be indicated for certain levels. 
EXAMPLE 8 
Non-invasive In Vivo Identification of the Presence 
20 
65 of Illegal Narcotics 
A portable device can be used to hold the optical genera- 
tion and measurement system. The device can be readily 
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carried by state or federal police enforcement agencies (or 
hospitals including medical examiners for autopsy) and 
conveniently used when a suspect is evaluated for potential 
illegal possession of drugs. In operation, the device can be 
configured as a headset with the display and light transmis- 
sion path positioned in front of the eye(s) of the subject. The 
subject can be instructed to read or identify the text or object 
encoded or displayed in the device as the fixation target in 
the headset over the eye or eyes. The device may include an 
auto or manual focus to correct the vision in the device and 
to allow the subject to focus to the target as needed. When 
the subject verbally affirms the proper identification of the 
fixation target, the device can be operated to obtain a 
reading. Almost instantaneously, the police officer can have 
quantitative results of whether the suspect has inhaled, 
ingested, injected, or otherwise consumed an illegal nar- 
cotic. It is anticipated that concentrations in the range of 
between about 0.001-1% (in the AH) or higher in the 
conjunctiva vessel (i.e., in the blood volume) may be quan- 
tified. Drugs present in small quantities (such as the pico- 
molar range) may be able to be identified (or the bodies’ 
reaction thereto identified thereby identifying the drug) but 
may not be able to be reliably quantified. 
It is noted that illegal narcotics may vary jurisdiction to 
jurisdiction and the device can be programmed according to 
the laws of the jurisdiction of use. Examples of illegal 
narcotics include opiate-based drugs such as cocaine in 
several forms such as crack, powder, and the like, and other 
drugs such as LSD, pcp, angel dust, marijuana, and others. 
It is anticipated that the most commonly used or street 
available illegal drugs or abused prescription drugs can be 
analyzed to predetermine the Raman signature as discussed 
above and these reference signature standards for these 
substances stored for reference to the in situ reading 
obtained on the suspect. 
In certain embodiments, the device and method can 
include assessing both, the brain alcohol (or blood alcohol) 
level of the suspect, and the presence of an illegal narcotic 
with one reading. Further, the present invention can be used 
to develop legal limits for other non-alcohol products so as 
to ascertain whether an individual is impaired for improved 
safety on the roadways. 
If an illegal narcotic is identified or if the alcohol level is 
above the legal limit, (the legal limit can be programmed for 
each state or locality), a documentary arrest record can be 
generated with a date and time stamp encoded onto the 
measurement record which can be automatically generated 
and electronically stored or printed. 
EXAMPLE 9 
Determination and/or Identification of Drug or 
Steroid Use 
In lieu of conventional urine tests, the present invention 
can be used to screen potential employees for drug use, or 
to assure employees are drug or alcohol free prior to 
allowing them to operate equipment (such as airplanes, 
trains, buses, subways, or other mass transit systems or 
heavy equipment and the like). This convenient and non- 
invasive screening may be a suitable testing system to help 
assure that the operators entrusted with the lives of others are 
not operating in an impaired state. 
The present invention can also be used to screen athletes 
for banned substances prior to competitions or at periodic or 
audit intervals, and/or to screen parolees for violation of 
parole. Indeed, the readings can be obtained locally and then 
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electronically relayed to a remote monitoring station where 
the results can be analyzed and proper authorities alerted of 
a positive test. 
EXAMPLE 10 
Identification of Ingested Poison(s) 
Similar to Example 8 ,  an in situ reading can be taken on 
an initial evaluation of a poison suspect, either by a para- 
medic at a home or in route to a hospital, or by a clinician, 
lo such as at an Emergency Room, to allow a relatively fast 
triage assessment of whether one or more poisons are 
present in the body. One reading may be able to identify one 
or more of several different signature peaks associated with 
several different poisons. The poisons may be common 
household products such as different medications, or a 
pesticide/herbicide, a cleaning agent, or antifreeze. By pre- 
evaluating the Raman signature of a plurality of common 
substances and electronically storing the data associated 
therewith in an electronic poison control reference library, 
2o the methods and devices of the present invention can decon- 
volute the in situ obtained Raman spectrum signal to build 
or match a signal pattern with the Raman reference stan- 
dards. Based upon the substances with signatures, which 
substantially match the in situ Raman signal, probable or 
25 possible substances can be identified (or to exclude other 
suspect substances). Knowing which of the chemicals or 
substances have the profile signature closest to the in situ 
obtained signature, the Raman signal(s) allows for the 
identification of which poisons may be in the body. The 
30 match can be based on a computational comparison of peaks 
or a graphical comparison. For example, the match can be 
carried out by matching the peaks or line shape profile across 
the spectrum of interest via best-fit curves or statistical 
correlation methods can identify products which align or 
35 match that of the data from the subject. A list of substances 
with associated probability ratings can be provided to the 
clinician. 
In addition, a quantitative determination of the amount of 
4o the identified substance or substances in the body may be 
able to be made depending on the strength of the signal 
(stronger signals typically indicate higher concentrations). 
In one embodiment, the Raman signature of a selected 
metabolite can be reviewed to see if the level is carcinogenic 
45 in the subject. For example, antifreeze (ethylene glycol) can 
be toxic to the liver. If it is identified that the either ethylene 
glycol was ingested or that the liver is emitting toxins or 
products, a treatment such as alcohol can be administered to 
offset the toxicity of the poison. Similarly, for other 
embodiments, the substance or drug itself may not be 
detectable in minute quantities in the body (typically in the 
pic0 or micro molar range). However, it may be possible to 
detect either a constituent of the substance of interest, or a 
physiologic reaction to the substance, to see if it is in an 
55 elevated level in the body (due to the body breaking down 
or reacting to the substance). 
The foregoing is illustrative of the present invention, and 
is not to be construed as limiting thereof. The invention is 
defined by the following claims, with equivalents of the 
5 
60 claims to be included therein. 
We claim: 
1. An in vivo method for monitoring the blood brain 
obtaining a Raman spectrum of a selected region in the 
monitoring the dynamics of the blood brain barrier of the 
barrier dynamics of a subject, comprising the step of  
65 eye of the subject; and 
subject based on the obtained Raman spectrum. 
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2. A method according to claim 1, further comprising the 
step of administering a non-specific marker to the subject 
selected for its normal reluctance to cross the blood brain 
barrier under a normal condition, and wherein said moni- 
toring step comprises detecting the presence of the non- 5 
specific marker in the selected region of the eye of the 
subject after the administering step based on the obtained 
Raman spectrum. 
3. A method according to claim 1, further comprising the 
steps o f  
altering the dynamics of the blood brain barrier of the 
subject from a normal condition; and 
administering a quantity of a selected therapeutic agent to 
a subject for treatment of condition in the brain or 
neurologic system after said altering step. 
comparing the Raman spectrum from said detecting step 
to predetermined reference spectrums corresponding to 
the non-specific marker; and 
identifying the presence of the non-specific marker in the 
Raman spectrum of said detecting step to indicate that 
the dynamics of the blood brain barrier have changed. 
18, A method according to claim 17, wherein said detect- 
ing step is carried out by illuminating the aqueous humor of 
the eye, 
19. A method according to claim 17, wherein said detect- 
ing step is carried out by illuminating the vitreous humor of 
the eye. 
20, A method according to claim 16, wherein said detect- 
ing step is carried out when the subject is exposed to 
10 
1s elevated ambient pressures. 4. A method according to 3, further comprising the 21, A method according to claim 17, further comprising step of returning the blood brain barrier to a substantially the step of 30 introducing a cytotoxic agent to the subject normal state after a sufficient quantity of the therapeutic after said identifying step. agent has been delivered to the brain. 
5 ,  A method according to claim 3, wherein said obtaining 22. A method according to claim 16, wherein said moni- 
step is repeated a plurality of times. 20 toring step is carried out when the subject is exposed to 
6. A method according to claim 3, wherein said obtaining gravity deficient environments. 
step is performed before said administering step to confirm 23. Amethod according to claim 16, wherein said method 
that the dynamics of the brain have been successfully altered is carried out during drug trials to assess the impact of the 
and subsequently to confirm that the blood brain barrier is drug on the dynamics of the blood brain barrier of the 
returned to a substantially normal condition. 
7. A method according to claim 3, wherein said method 24. A method according to claim 17, wherein said method 
further comprises the step of assessing the dose amount of is carried out when the brain of the subject has been exposed 
the therapeutic agent delivered to the brain. to a trauma injury to determine whether there is an alteration 
8. A method according to claim 1, wherein the selected of the dynamics of the blood brain barrier, 
region of the eye comprises the aqueous humor. 25. A method for identifying an alteration in the blood 
9. A method according to claim 1, wherein the selected brain barrier of a biological subject, comprising the steps o f  
non-invasively obtaining a first in vivo Raman spectrum region of the eye comprises the vitreous humor. 
of the aqueous humor of the subject; 10. A method according to claim 1, wherein the selected region of the eye comprises a conjunctive vessel. 
11, Amethod according to claim 1, wherein the therapeu- non-invasively obtaining a second in vivo Raman spec- 
trum of the aqueous humor of the subject; and tic agent is a cytotoxic agent suitable for treating a cancer in 
the brain. comparing the first and second Raman spectrums to detect 
12. A method according to claim 3, wherein said altering an alteration in the function of the blood brain barrier. 
step is carried out by introducing a chemical to the subject 26. A method for identifying an alteration or abnormality 
to temporarily open the blood brain barrier which allows in the blood brain barrier of a biological subject, comprising 
larger molecules to pass therethrough. 
13, A method according to claim 3, wherein said altering non-invasively obtaining a first in vivo Raman spectrum 
step is carried out by increasing the intracranial pressure of of the aqueous humor of the subject; 
the subject. obtaining at least one reference spectrum of an in vitro 
14. A method according to claim 3, wherein the thera- sample representing the aqueous humor and compris- 
peutic agent is directed to treating brain cancer. ing at least one selected analyte; 
15. A method of non-invasively monitoring the blood comparing the in vivo Raman spectrum to the reference 
brain barrier of a subject, comprising the steps o f  spectrum; and 
generating an excitation beam; identifying an abnormality in the blood brain barrier 
focusing the excitation beam of said generating step into based on the detected presence of at least one selected 
the eye of the subject so that a selected region is analyte in the aqueous humor based on the comparison 
illuminated; of the in vivo and reference Raman spectra. 
detecting a R~~~~ spectrum corresponding to the illumi- 27. Amethod according to claim 26, wherein said the least 
nated region; and one analyte is a physiological compatible non-specific 
monitoring the blood brain barrier dynamics during expo- 55 marker which is selected based on its natural reluctance to 
sure to selected conditions based on said detecting step. pass through the brain barrier. 
16, A method according to claim 15, wherein said moni- 28. A non-invasive method for determining the alcohol 
toring step comprises assessing whether the dynamics of the level in a subject, comprising the steps Of: 
blood brain barrier are altered sufficiently to allow at least generating an excitation beam; 
one selected analyte, which would normally be inhibited 60 focusing the excitation beam of said generating step into 
from traveling through the blood brain barrier, to pass into the anterior chamber of an eye of the subject so that 
the intracranial spinal fluid through the blood brain barrier. aqueous humor in the anterior chamber is illuminated; 
17. Amethod according to claim 16, wherein said method detecting a Raman spectrum corresponding to the illumi- 
further comprises the steps of  nated aqueous humor; 
administering a non-specific marker to the subject, the 65 comparing the Raman spectrum from said detecting step 
non-specific marker being selected for its normal reluc- to reference spectrums corresponding to different con- 
tance to pass through the blood brain barrier; centrations of alcohol; and 
2s subject. 
30 
35 
40 the steps o f  
45 
US 6,574,501 B2 
43 
assessing the brain alcohol level in the subject based on 
29. A non-invasive method for identifying an unknown 
generating an excitation beam; 
focusing the excitation beam of said generating step into 
a selected region in the eye of the subject so that the 
selected region is illuminated; 
detecting a Raman spectrum corresponding to the illumi- 
nated selected region; 
comparing the Raman spectrum from said detecting step 
to reference spectra corresponding to different concen- 
trations of a plurality of different substances; and 
identifying the unknown substance in the subject based on 
said detecting and comparing steps, wherein the 
selected region of the eye is one of the aqueous humor 
and a conjunctiva vessel, said method further compris- 
ing the step of estimating the amount of the at least one 
analyte of interest in the cerebral spinal fluid of the 
subject based on said detecting, comparing, and iden- 
tifying steps. 
30. A method for non-invasively directly measuring the 
blood level of a substance of interest in a subject, comprising 
the steps of  
obtaining a plurality of reference Raman spectrums of 
varying concentrations of at least one analyte of inter- 
est; 
said detecting and comparing steps. 
poison in a subject, comprising the steps of  
generating an excitation beam; 
focusing the excitation beam of said generating step into 
at least one conjunctiva vessel in the eye of the subject 
so that the vessel is illuminated; 
detecting a Raman spectrum corresponding to the illumi- 
nated vessel; 
comparing the Raman spectrum from said detecting step 
to the reference spectrums; and 
determining the blood level of the at least one analyte 
based on said detecting and comparing steps. 
31. A method according to claim 30, wherein the refer- 
ence spectrums comprise a plurality of different Raman 
spectrums generated for each of the at least one analyte at 
different concentrations based on in vitro samples thereof. 
32. A method according to claim 30, wherein said exci- 
tation beam pulse is low energy. 
33. Amethod according to claim 30, wherein said at least 
one analyte is glucose. 
34. Amethod according to claim 30, wherein said at least 
one analyte is a plurality of different selected analytes, and 
wherein said method further comprises, for a single detect- 
ing step, identifying the presence of at least one of the 
different plurality of substances in the subject. 
35. Amethod according to claim 30, wherein said at least 
one analyte is alcohol. 
36. A method according to claim 30, further comprising 
the step of subtracting a fluorescence spectrum from said 
vessel Raman spectrum to produce a difference spectrum. 
37. A method according to claim 28, wherein said iden- 
tifying step identifies an elevated antibody level in the 
subject. 
38. A method according to claim 28, wherein said iden- 
tifying step detects the presence of a poison in the subject. 
39. A method according to claim 28, wherein the refer- 
ence spectra of selected analytes of interest are based on 
selected household chemicals. 
40. A method according to claim 28, wherein the refer- 
ence spectra of selected analytes of interest are of illegal 
narcotics. 
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41. A method according to claim 28, wherein said refer- 
ence spectra for each analyte of interest comprises spectra 
generated from a Raman spectra training set comprising at 
least 10 in vitro aqueous humor samples for each analyte of 
s interest with each of the at least 10 samples including 
different amounts of the analyte therein, and an analyte level 
corresponding to each of the samples. 
42. An apparatus for the non-invasive determination of a 
level of an analyte of interest in a subject, comprising: 
10 
1s 
20 
2s 
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3s 
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a light source for generating an excitation beam; 
an optical system operatively associated with said laser 
fo; directing said-excitation beam into the eye of said 
subject so that a selected region in the eye is sufficiently 
illuminated to generate a detectable Raman spectrum 
thereof; 
detector operatively associated with said optical system 
and configured to detect a Raman spectrum from the 
selected region in the eye; 
system processor operably associated with said detector 
and including computer programs with computer pro- 
gram code for comparing the detected Raman spectrum 
signal to reference spectrums associated with at least 
one analyte of interest to identify the presence or 
absence of at least one analyte of interest in the subject, 
wherein said system processor comprises computer 
program code for determining the in vivo brain level of 
at least one analyte of interest for the subject based on 
the detected Raman spectrum; 
housing configured to overlie at least one eye of a 
subject during use and to house said optical system and 
said detector therein, so that, in position, the optical 
system is spaced apart from the eye of the subject; and 
focus adjustment unit including a visual display adapted 
to display visual indicia thereon, mounted in said 
housing so that, in operation, the visual indicia on said 
display is visible to a user to allow a user to look at a 
visual reference presented thereon to allow the visual 
indicia to be focused so that the excitation beam can be 
directed to the appropriate location in the eye of the 
subject and so that said detector can detect the gener- 
ated Raman spectrum. 
43. An apparatus according to claim 35, wherein said 
system processor comprises means for subtracting a fluo- 
4s rescence spectrum for said Raman spectrum to produce a 
difference spectrum. 
44. An apparatus according to claim 35, wherein said 
optical system is configured to illuminate the aqueous humor 
of the eye. 
45. An apparatus according to claim 35, wherein said 
optical system is configured to illuminate the vitreous humor 
of the eye. 
46. An apparatus for the non-invasive determination of a 
blood level of an analyte of interest in a subject, comprising: 
a light source for generating an excitation beam; 
an optical system operatively associated with said laser 
for directing said excitation beam into the eye of said 
subject so that a selected region in the eye is sufficiently 
illuminated to generate a detectable Raman spectrum 
thereof, wherein said optical system is configured to 
illuminate at least one blood vessel in the conjunctiva 
of the eye; 
a detector operatively associated with said optical system 
and configured to detect a Raman spectrum from the at 
least one blood vessel in the conjunctiva of the eye; 
a system processor operably associated with said detector 
and including computer programs with computer pro- 
so 
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gram code for comparing the detected Raman spectrum 
signal to reference spectrums associated with at least 
one analyte of interest to identify the presence or 
absence of at least one analyte of interest in the subject; 
a housing configured to overlie at least one eye of a 
subject during use and to house said optical system and 
said detector therein, so that, in position, the optical 
system is spaced apart from the eye of the subject; and 
a focus adjustment unit including a visual display adapted 
to display visual indicia thereon, mounted in said 
housing so that, in operation, the visual indicia on said 
display is visible to a user to allow a user to look at a 
visual reference presented thereon to allow the visual 
indicia to be focused so that the excitation beam can be 
directed to the appropriate location in the eye of the 
subject and so that said detector can detect the gener- 
ated Raman spectrum. 
47. An apparatus according to claim 39, wherein said 
excitation beam has a wavelength of from about 600 to 900 
nanometers. 
48. An apparatus according to claim 39, wherein said 
excitation beam is low energy. 
49. An apparatus according to claim 39, wherein said 
excitation beam has a wavelength of about 633 nm. 
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50. An apparatus according to claim 39, wherein the 
computer program reference spectrums are produced with a 
training set of Raman spectra corresponding to at least 20 
aqueous humor samples of varying concentrations of ana- 
lytes therein for each of a plurality of different selected 
analytes and an identified blood level of said analyte of 
interest for each of said samples. 
51. An apparatus according to claim 50, wherein said 
analyte of interest is alcohol. 
52. An apparatus according to claim 35, wherein said at 
least one analyte is cytotoxic and/or a poison. 
53. An apparatus according to claim 42, wherein said the 
poison comprises at least one of a household chemical, 
pesticide, herbicide, or petroleum product. 
54. An apparatus according to claim 35, wherein said at 
least one analyte is from a poisonous plant. 
55. An apparatus according to claim 35, wherein said at 
least one analyte is a drug. 
56. An apparatus according to claim 35, wherein said 
housing is configured and sized to fit onto and rest against 
the head of the subject during operation. 
57. An apparatus according to claim 40, wherein said 
housing is configured and sized to be a hand held device. 
* * * * *  
